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Introduction {#sec001}
============

Bacterial vaginosis (BV) is an imbalance or dysbiosis of the vaginal microbiome that affects approximately 29% of US women \[[@pbio.3000788.ref001]\]. BV is characterized by low levels of "beneficial" lactobacilli and overgrowth of bacteria from diverse taxonomic groups \[[@pbio.3000788.ref002]--[@pbio.3000788.ref004]\]. Women with BV are at higher risks of various adverse health outcomes and infection-related complications and are more likely to be vaginally colonized by the potentially pathogenic bacterial taxa that cause these infections \[[@pbio.3000788.ref005]--[@pbio.3000788.ref012]\]. For example, BV-positive women and those with amniotic fluid infections and preterm labor are more likely to be vaginally colonized by *Fusobacterium nucleatum* \[[@pbio.3000788.ref003],[@pbio.3000788.ref009],[@pbio.3000788.ref013]\]. Unfortunately, mechanisms of pathogen colonization within the BV niche are poorly understood. It is widely held that a healthy microbiome thwarts the entry of potentially pathogenic members into the community (referred to as "colonization resistance") and that the loss of this "colonization resistance" plays a vital role in the development of vaginal dysbiosis \[[@pbio.3000788.ref014]\]. We suggest that bacterial communities of the dysbiotic vaginal niche also rely on mutually supporting metabolic interactions to stabilize communities, as described in other microbial ecosystems \[[@pbio.3000788.ref015]--[@pbio.3000788.ref019]\].

One biochemical characteristic of BV is the presence of sialidase activity in vaginal fluids \[[@pbio.3000788.ref020]--[@pbio.3000788.ref022]\]. Sialidase activity may contribute to complications of BV. For example, high sialidase activity in vaginal fluids is associated with increased risk of preterm birth \[[@pbio.3000788.ref021],[@pbio.3000788.ref023]\]. Sialidases play diverse roles in bacterial--host interactions, coinfection, and dysbiosis in oral, gastrointestinal, and airway systems \[[@pbio.3000788.ref017],[@pbio.3000788.ref018],[@pbio.3000788.ref024]--[@pbio.3000788.ref030]\]. We hypothesize that bacterial sialidases also play important roles in pathogen colonization and dysbiosis in the vagina. Bacterial sialidases liberate mucosal carbohydrates called sialic acids from glycan chains of secreted mucus components and cell surface glycoproteins. In BV, vaginal mucus secretions have higher levels of free/liberated sialic acid \[[@pbio.3000788.ref031]--[@pbio.3000788.ref033]\]. *Gardnerella vaginalis*, an abundant species in BV, produces sialidases to release and forage sialic acids from glycan chains of sialoglycoproteins \[[@pbio.3000788.ref031],[@pbio.3000788.ref034]\]. However, not all bacteria that catabolize sialic acids express sialidase \[[@pbio.3000788.ref035],[@pbio.3000788.ref036]\]. Here, we examine the idea that in the sialidase-positive vaginal niche, the ability to utilize free sialic acid may provide fitness benefits to sialidase-negative potential pathogens, facilitating their growth and persistence.

*F*. *nucleatum* is a gram-negative spindle-shaped obligate anaerobe that is ubiquitous in the human mouth but also one of the most commonly isolated microorganisms from amniotic fluid of women in preterm labor \[[@pbio.3000788.ref037]--[@pbio.3000788.ref039]\]. Although the prevailing view is that *F*. *nucleatum* reaches the amniotic fluid through an oral--hematogenous route \[[@pbio.3000788.ref040]\], vaginal colonization with *F*. *nucleatum* is also a risk factor for amniotic fluid infection and preterm birth \[[@pbio.3000788.ref013]\]. *F*. *nucleatum* is not known to express sialidase of its own \[[@pbio.3000788.ref041]\], but it commonly resides among sialidase-producing bacteria in the mouth, gut, and vagina \[[@pbio.3000788.ref042]--[@pbio.3000788.ref046]\]. Some *F*. *nucleatum* strains also encode putative sialic acid catabolic pathways, although functional characterization of the corresponding gene products is still limited \[[@pbio.3000788.ref047]--[@pbio.3000788.ref051]\]. We hypothesized that *F*. *nucleatum* may derive nutritional benefit from host sialoglycans when exogenous sialidases produced by other bacteria are present. Here, we use in vitro approaches and a mouse model to show that *F*. *nucleatum* cannot obtain sialic acid from intact glycoconjugates, in which sialic acid is bound to underlying glycans, but can nevertheless benefit from sialic acid catabolism when colonizing a sialidase-positive vaginal niche. Unexpectedly, our models also led to the discovery that *F*. *nucleatum* does not act in a simple one-way relationship with sialidase-producing bacteria, but rather engages in a mutually beneficial relationship. In fact, the data demonstrate that *F*. *nucleatum* exposure to vaginal communities may encourage features of dysbiosis (increased sialidase activity and *G*. *vaginalis* abundance) in susceptible vaginal communities. These results may help explain why women with BV are at increased risk of vaginal colonization by some pathogens such as *F*. *nucleatum*. Additionally, our data suggest that mutual reinforcement between bacterial species, made possible in part through metabolite cross-feeding, promotes pathogen colonization and vaginal dysbiosis.

Results {#sec002}
=======

Subsets of *F*. *nucleatum* consume free sialic acid {#sec003}
----------------------------------------------------

An organism's ability to colonize an already-occupied niche depends on its ability to access nutrients for growth. Some mucosal bacteria forage on host sialic acids by importing them from the extracellular environment through a sialic acid transporter and then converting them to *N*-acetyl-mannosamine and pyruvate using a sialate lyase (*N*-acetylneuraminate lyase, NanA) \[[@pbio.3000788.ref052]--[@pbio.3000788.ref054]\]. Recent studies suggest that *F*. *nucleatum* may encode these functionalities \[[@pbio.3000788.ref048]--[@pbio.3000788.ref050]\]. Here, we used an amino acid sequence of the well-characterized *Escherichia coli* NanA (MG1655, GenBank: AAC76257.1) to search for homologous proteins in *F*. *nucleatum*. A bioinformatic analysis of 28 *F*. *nucleatum* proteomes spanning several subspecies identified NanA homologs in most members of the subspecies *nucleatum* and *vincentii* and some strains of *animalis*, but not in the subspecies *polymorphum* ([S1 Fig](#pbio.3000788.s001){ref-type="supplementary-material"}). Functional analyses of free sialic acid foraging among a collection of *F*. *nucleatum* strains were consistent with these genomic predictions. Members of the subspecies *nucleatum* and *vincentii* were competent foragers of free sialic acid, but the tested strains of *animalis* and *polymorphum* were not ([Fig 1A](#pbio.3000788.g001){ref-type="fig"}). Analyses of other members of the order Fusobacteriales suggested that some species in addition to *F*. *nucleatum* (for example, *F*. *mortiferum*) may catabolize sialic acids, but sialic acid consumption is not ubiquitous.

![Analysis of sialic acid utilization by Fusobacteria and functional evidence of *F*. *nucleatum*-encoded sialate lyase (*nanA*).\
(A) Amount of sialic acid remaining in the growth medium 24--48 h postinoculation of different Fusobacteria (as indicated) or uninoculated media control. Subspecies of *F*. *nucleatum* are indicated in blue text. All Fusobacteria were grown in supplemented Columbia medium with free sialic acid added (Neu5Ac, 100 μM)---medium that was also used as uninoculated control. *E*. *coli* (MG1655), a known sialic acid consumer, cultured in LB medium with added free sialic acid (Neu5Ac, 100 μM) was included as a positive control. Error bars shown are standard deviation of the mean from 3 independent experiments. (B--C) *E*. *coli* MG1655 *ΔnanA* was complemented with empty vector, *E*. *coli nanA* or putative *nanA* from *F*. *nucleatum* ATCC23726 (GenBank accession EFG95907). Data shown are representative of 3 independent experiments. (B) Growth was assessed in minimal media with sialic acid by measuring absorbance at 600 nm. (C) Lysates of the *E*. *coli nanA* mutant with empty vector or the complemented strain were incubated with sialic acid (Neu5Ac), and its disappearance was monitored over time by fluorescent derivatization (with DMB) followed by HPLC. The underlying numerical data for this figure can be found in [S1 Data](#pbio.3000788.s013){ref-type="supplementary-material"}. Strain names: FQG51A, JM6, JM4, JMH52, JMP2A, JMSY1, SYJL4. Description of bacterial strains can be found in [S1 Table](#pbio.3000788.s011){ref-type="supplementary-material"}. ATCC, American Type Culture Collection; DMB, 1,2-diamino-4,5-methylenedioxybenzene; *E*.*c*., *E*. *coli*; *F*.*n*., *F*. *nucleatum*; HPLC, high-performance liquid chromatography; LB, lysogeny broth; *nanA*, *N*-acetylneuraminate lyase; Neu5Ac, *N*-acetylneuraminic acid; OD, optical density.](pbio.3000788.g001){#pbio.3000788.g001}

To test whether the *nanA* identified from *F*. *nucleatum* strain American Type Culture Collection (ATCC) 23726 encodes a functional sialic acid lyase, the gene was cloned into an *E*. *coli* expression plasmid and transformed into a *ΔnanA* deletion mutant of *E*. *coli* \[[@pbio.3000788.ref036]\] ([S1 Table](#pbio.3000788.s011){ref-type="supplementary-material"}). On its own, *E*. *coli ΔnanA* (containing an empty vector) was unable to grow on sialic acid as a sole carbon source ([Fig 1B](#pbio.3000788.g001){ref-type="fig"}). However, growth was restored by complementation with plasmids containing either *E*. *coli nanA* or *F*. *nucleatum nanA*. Sialate lyase activity was also assayed in clarified lysates by measuring the disappearance of *N*-acetylneuraminic acid (Neu5Ac) over time. The amount of remaining sialic acid was measured by fluorescent derivatization and high-performance liquid chromatography (HPLC) analysis by comparison to synthetic Neu5Ac standards processed in parallel. As expected, the *E*. *coli ΔnanA* strain containing empty vector did not have sialic acid lyase activity ([Fig 1C](#pbio.3000788.g001){ref-type="fig"}). However, in reactions with lysates from the complemented strains, \>80% of the sialic acid was depleted within 30 min ([Fig 1C](#pbio.3000788.g001){ref-type="fig"}). These results demonstrate that *F*. *nucleatum* NanA (GenBank: EFG95907.1) functions as a sialate lyase.

In *F*. *nucleatum* (ATCC23726), the *nanA* gene is found downstream of a putative sialic acid transporter (*siaT*) in a gene cluster encoding other enzymes with predicted roles in carbohydrate metabolism ([S2 Table](#pbio.3000788.s012){ref-type="supplementary-material"}). To further assess the importance of *F*. *nucleatum* sialic acid catabolism, a minimal suicide vector targeting the *siaT* gene was designed for insertional mutagenesis in a streptomycin-resistant (Sm^R^) isolate of *F*. *nucleatum* ATCC23726 ([Fig 2A](#pbio.3000788.g002){ref-type="fig"}). This plasmid was used to generate a strain in which *siaT* was disrupted (Ω*siaT*; [Fig 2B](#pbio.3000788.g002){ref-type="fig"}). Hereafter, the *F*. *nucleatum* wild type (WT) and Ω*siaT* mutant are referred to as "WT" and "Ω*siaT*." Analysis of the transcripts by reverse transcription--quantitative PCR (RT-qPCR) throughout this gene cluster in the Ω*siaT* mutant showed that the transcription of genes upstream of *siaT* were unaffected by the insertion ([Fig 2C](#pbio.3000788.g002){ref-type="fig"}). As expected, there was an approximately 5-fold reduction in transcript of 3 genes downstream of the mutation site that are involved in sialic acid catabolism. Consistent with these findings, Ω*siaT* was unable to forage on free sialic acid (Neu5Ac) ([Fig 2D](#pbio.3000788.g002){ref-type="fig"}), even though both strains grew similarly in the nutrient-rich media used for this experiment ([S2 Fig](#pbio.3000788.s002){ref-type="supplementary-material"}). *F*. *nucleatum* is a fastidious anaerobe, and single-carbon--source experiments are not feasible as an experimental strategy. Therefore, we developed a nutrient-limited media containing some of the base components of Columbia media, as described in the Methods. Reducing the nutrient content of the growth media made it possible to investigate the impact of sialic acid foraging on the growth of *F*. *nucleatum* when resources are limited. Experiments were performed in nutrient-limited media with or without added carbohydrate sources. Briefly, WT and Ω*siaT* were inoculated into a nutrient-limited medium, either with no added carbohydrate or with added monosaccharides---glucose or free sialic acid (Neu5Ac). Both WT and Ω*siaT* grew poorly in low-carbohydrate medium, reaching a plateau at an optical density (OD)~600~ of approximately 0.25, and both grew well in medium containing glucose, reaching a plateau at an OD~600~ of \>0.6. In contrast, in the medium containing free sialic acid as the main source of carbohydrate, Ω*siaT* showed a substantial growth defect, reaching an OD~600~ of only approximately 0.25, whereas WT grew to an OD~600~ of \>1.0 ([Fig 2E](#pbio.3000788.g002){ref-type="fig"}). Together, these data demonstrate the genetic basis for sialic acid catabolism in *F*. *nucleatum* and illustrate the benefit of sialic acid catabolism under nutrient-limited conditions.

![Insertional mutagenesis to disrupt sialic acid catabolic pathway in *F*.*n*. ATCC23726 and growth analysis in nutrient-limited media.\
(A) Schematic showing integration of plasmid containing *siaT* insert (pLR25) into the *F*.*n*. chromosome. Positions of Fwd and Rev primers used for confirming integration of plasmid are also indicated. (B) Agarose gel image with the expected PCR product confirming integration of plasmid into the *siaT* locus. (C) RT-qPCR analysis of genes flanking *siaT* in *F*.*n*. shows low expression of transcripts of putative sialic acid catabolism genes downstream of the plasmid insertion site. Difference in expression of each gene between *F*.*n*. WT versus Ω*siaT* was analyzed by the ΔΔCt method using the 16S rRNA gene for normalization. Fwd and Rev primer binding sites are indicated by arrows in the schematic below the graph. (D) Functional assessment of the WT and Ω*siaT* strains confirms disruption of sialic acid catabolism. Shown is the concentration of sialic acid (Neu5Ac) remaining in the medium 24 hpi. Sialic acid consumption by *F*.*n*. WT and Ω*siaT* was studied in supplemented Columbia media with free sialic acid added. (E) Growth of *F*.*n*. WT and Ω*siaT* in nutrient-limited media with no added carbohydrates (carbs) or with the indicated carbohydrates added. All data shown are representative of 2 or more independent experiments. The underlying numerical data for this figure can be found in [S1 Data](#pbio.3000788.s013){ref-type="supplementary-material"}. Error bars represent standard deviation from the mean. Description of the plasmids and cloning vectors used for construction of new suicide plasmid pLR25 can be found in [S1 Table](#pbio.3000788.s011){ref-type="supplementary-material"}. Description of the genes in the predicted sialic acid catabolic gene cluster can be found in [S2 Table](#pbio.3000788.s012){ref-type="supplementary-material"}. ATCC, American Type Culture Collection; *catP*, chloramphenicol acetyltransferase; Fwd, forward; *F*.*n*., *F*. *nucleatum*; hpi, hours postinoculation; *nanA*, *N*-acetylneuraminate lyase; Neu5Ac, *N*-acetylneuraminic acid; Rev, reverse; RT-qPCR, reverse transcription--quantitative PCR; *siaT*, predicted sialic acid transporter; WT, wild type.](pbio.3000788.g002){#pbio.3000788.g002}

*F*. *nucleatum* has restricted access to sialoglycans {#sec004}
------------------------------------------------------

Consistent with a previous study showing that 39 cultured *F*. *nucleatum* isolates all lacked sialidase activity \[[@pbio.3000788.ref041]\], our bioinformatic analysis of *F*. *nucleatum* proteomes revealed no putative sialidases in this taxon. In an in vitro assay, using the abundant BV bacterium and known sialidase producer *G*. *vaginalis* as a positive control, we found that anaerobically grown *F*. *nucleatum* could not cleave a fluorogenic sialic acid substrate ([Fig 3A](#pbio.3000788.g003){ref-type="fig"}). Along with previous findings, these results establish that *F*. *nucleatum* lacks its own sialidase activity. We therefore hypothesized that its ability to access and utilize sialic acid bound to host glycans for growth would require exogenous sialidase provided by bacteria living within the same niche ([Fig 3B](#pbio.3000788.g003){ref-type="fig"}). To test this, *F*. *nucleatum* strains were inoculated in nutrient-limited media with added 3′-sialyllactose (3SL, a trisaccharide glycan containing α2--3--linked Neu5Ac) in the presence or absence of an exogenous purified sialidase from *Arthrobacter ureafaciens*. Here, we observed that both *F*. *nucleatum* WT and Ω*siaT* showed little growth in sialoglycan-rich media without exogenous sialidase. In contrast, upon the addition of sialidase, the WT strain grew more substantially (reaching an OD~600~ \>0.8) in sialoglycan-containing medium. The Ω*siaT* mutant, unable to consume sialic acids, continued to exhibit limited growth even in the presence of sialidase (only reaching an OD~600~ = approximately 0.4) ([Fig 3C](#pbio.3000788.g003){ref-type="fig"}). As described in the Methods, derivatization without prior acid hydrolysis measures free Neu5Ac, while derivatization following acid hydrolysis, which releases bound Neu5Ac from sialoglycans, measures the total Neu5Ac (Bound Neu5Ac = Total Neu5Ac − Free Neu5Ac). Measurements of the media at the endpoint showed that sialic acids remained in the bound form in the absence of exogenous sialidase, precluding *F*. *nucleatum* from capitalizing on this resource ([Fig 3D](#pbio.3000788.g003){ref-type="fig"}). With the addition of sialidase, sialic acids were liberated into the free form, but only WT *F*. *nucleatum* was able to deplete the liberated resource. In contrast, Ω*siaT* was unable to deplete sialic acids and did not receive a growth benefit. While the sialoglycan substrate used here contains α2--3--linked sialic acids, *Arthrobacter* and *Gardnerella* sialidases are able to access both α2--3-- and α2--6--linked sialic acids \[[@pbio.3000788.ref034],[@pbio.3000788.ref055]\]. Together, these data demonstrate that *F*. *nucleatum* can access and consume sialic acids from sialo-glycoconjugates, only if sialidase activity from an exogenous source is available to first liberate sialic acids into the free form.

![*F*.*n*. accesses bound sialic acid from glycan chains, but only when liberated by exogenous sialidases.\
(A) Analysis of cell-associated sialidase activity of anaerobically cultured *G*. *vaginalis* JCP8151B and *F*.*n*. ATCC23726 strains using fluorogenic 4MU-Neu5Ac substrate. (B) Working hypothesis: sialidase producers in the vaginal microbial community release free sialic acids (red diamonds) from host glycoconjugates, which may be accessed by *F*.*n*., which does not produce sialidase. More information about *F*.*n*. genes shown in the predicted sialic acid catabolic gene cluster and the enzymes they encode can be found in [S2 Table](#pbio.3000788.s012){ref-type="supplementary-material"}. (C) Growth of *F*.*n*. ATCC23726 WT and Ω*siaT* in nutrient-limited media with added 3SL, in the absence of sialidase (no sialidase) or presence of exogenous *A*.*u*. sialidase. (D) Concentrations of remaining free and total sialic acid (Neu5Ac) in nutrient-limited media (with added 3SL, from experiment shown in C) that was either uninoculated or inoculated with *F*.*n*. WT or Ω*siaT* strain (in absence and presence of *A*.*u*. sialidase). Total and free sialic acid content was measured at approximately 48 h postinoculation. Bound sialic acids are inaccessible to *F*.*n*. except in the presence of exogenous sialidase. All data shown are representative of 3 independent experiments. The underlying numerical data for this figure can be found in [S1 Data](#pbio.3000788.s013){ref-type="supplementary-material"}. Error bars represent standard deviation from the mean. ATCC, American Type Culture Collection; *A*.*u*., *A*. *ureafaciens*; *F*.*n*., *F*. *nucleatum*; NanA, *N*-acetylneuraminate lyase; Neu5Ac, *N*-acetylneuraminic acid; OD, optical density; PBS, phosphate-buffered saline; *siaT*, predicted sialic acid transporter; WT, wild type; 3SL, 3′-sialyllactose; 4MU, 4-methylumbelliferone.](pbio.3000788.g003){#pbio.3000788.g003}

Sialic acid catabolism prolongs vaginal colonization by *F*. *nucleatum* {#sec005}
------------------------------------------------------------------------

The above findings supported our hypothesis that sialic acid catabolism may facilitate *F*. *nucleatum* colonization and persistence within sialidase-producing microbial communities. Although the vaginal microbiomes of women and laboratory mice are different, our previous measurements of sialidase activity in mouse vaginal washes suggested that some mice, like some women, harbor a sialidase-positive vaginal microbiome \[[@pbio.3000788.ref031]\]. However, only approximately 10% of animals in this prior study had sialidase activity in vaginal washes. To identify a vendor whose C57BL/6 mice had a more uniform sialidase-positive phenotype, vaginal washes from animals purchased from multiple vendors were tested for sialidase activity. Endogenous vaginal sialidase activity was present in most mice from Envigo but was rarely detectable in mice from 3 other vendors ([S3A Fig](#pbio.3000788.s003){ref-type="supplementary-material"}). Furthermore, Envigo mice had even more vaginal sialidase activity after treatment with β-estradiol, whereas mice from Jackson were sialidase-negative with or without β-estradiol treatment ([S3B Fig](#pbio.3000788.s003){ref-type="supplementary-material"}). This is relevant because our mouse model employs β-estradiol treatment, like most bacterial vaginal inoculation models \[[@pbio.3000788.ref031],[@pbio.3000788.ref056]--[@pbio.3000788.ref059]\].

To investigate whether sialidase activity in vaginal washes was of bacterial origin, we profiled the composition of the vaginal microbiotas of Jackson and Envigo mice. To increase the available biomass, we pooled vaginal washes from cohoused mice (4 pools/vendor), and a portion of each vaginal wash pool was cultured anaerobically, then frozen in cryoprotectant ([S1 Schematic](#pbio.3000788.s009){ref-type="supplementary-material"}). Corroborating our findings in individual vaginal washes, microbiota pools (cultured vaginal wash) from Envigo mice, but not Jackson mice, had high sialidase activity ([S3C Fig](#pbio.3000788.s003){ref-type="supplementary-material"}). The presence of sialidase activity in mixed cultures from Envigo mice is consistent with the hypothesis that sialidase is microbial and not host-derived. To further validate this hypothesis, we analyzed the mouse vaginal microbiota by sequencing the V1--V2 region of the gene encoding the 16S ribosomal subunit ([S3D Fig](#pbio.3000788.s003){ref-type="supplementary-material"}) (see [Methods](#sec009){ref-type="sec"} for V1--V2 rationale). DNA was extracted from both the original (uncultured) pooled wash material and from viable communities of bacteria (microbiota pools) derived from the cultured vaginal wash material ([S1 Schematic](#pbio.3000788.s009){ref-type="supplementary-material"}). In addition to the 16S sequencing analysis, the cultured microbiota pools were also plated on agar media, and the resulting colonies were picked into 96-well plates to perform sialidase activity assays. PCR and sequencing were also performed to identify colonies. Sequencing revealed that several of the uncultured vaginal wash pools and ex vivo-cultured communities from Envigo mice contained *Enterococcus casseliflavus/gallinarum*, whereas the corresponding samples from Jackson mice did not. Notably, colonies of *E*. *gallinarum* and *Bacteroides* spp. from cultured vaginal wash pools from Envigo mice expressed sialidase activity ([S3E Fig and S3F Fig](#pbio.3000788.s003){ref-type="supplementary-material"}). Furthermore, we previously isolated sialidase-positive *E*. *gallinarum* from mouse vaginal washes that contained sialidase activity \[[@pbio.3000788.ref020],[@pbio.3000788.ref031]\]. These findings are consistent with differences in vaginal sialidase activity between mice from the different vendors and confirm that C57BL/6 mice from Envigo exhibit vaginal sialidase activity arising from the endogenous microbiota. Finally, we note that estrogenized mice from Envigo were consistently sialidase-positive in 4 independent studies of mice purchased over 2 years and were therefore a relevant model to test our hypothesis.

To determine whether the ability to catabolize sialic acid contributes to *F*. *nucleatum* colonization or persistence within sialidase-producing microbial communities, Envigo mice were vaginally inoculated with *F*. *nucleatum* WT or Ω*siaT*, and vaginal washes were collected longitudinally for several weeks ([Fig 4A](#pbio.3000788.g004){ref-type="fig"}). Before inoculation, both the infection groups had similar amounts of sialidase activity ([Fig 4B](#pbio.3000788.g004){ref-type="fig"}). As early as 72 h postinoculation (hpi), and later at 6 days postinoculation (dpi) up to 8 dpi, Ω*siaT* had significantly lower titers than WT in Envigo mice ([Fig 4C](#pbio.3000788.g004){ref-type="fig"} and [S4 Fig](#pbio.3000788.s004){ref-type="supplementary-material"}). Sufficient vaginal wash material was available for sialic acid measurement at 8 dpi from some of the mice in each experimental group. Free sialic acid levels were similar between WT- and Ω*siaT*-inoculated mice. However, total sialic levels were lower in mice colonized with WT- compared to Ω*siaT*-inoculated mice ([S4 Fig](#pbio.3000788.s004){ref-type="supplementary-material"}). The latter comparison was underpowered with the number of samples available and did not reach statistical significance (*P* = 0.19). However, the lower levels of total sialic acid in mice with *F*. *nucleatum* WT are consistent with a depletion of sialic acid, a phenotype also observed in women with BV. Furthermore, Ω*siaT* exhibited a significant defect in vaginal persistence relative to the WT strain (*P* = 0.02; [Fig 4D](#pbio.3000788.g004){ref-type="fig"}). Similar to Envigo mice, *F*. *nucleatum* was also able to colonize sialidase-negative mice from Jackson Labs. However, there was no detectable benefit afforded by sialic acid catabolism in this setting, either in overall bacterial burden or persistence ([S5 Fig](#pbio.3000788.s005){ref-type="supplementary-material"}). We conclude from these experiments that the ability to catabolize sialic acid benefits *F*. *nucleatum* colonization and persistence in a sialidase-positive vaginal environment.

![Sialic acid catabolism encourages *F*. *nucleatum* colonization in mice with sialidase-positive vaginal microbiomes.\
(A) Time course of vaginal colonization with *F*. *nucleatum* ATCC23726. Open circles indicate vaginal wash collection which were used to monitor colonization status and sialidase activity at all time points. (B) Analysis of sialidase activity in vaginal washes of Envigo mice before inoculation with *F*. *nucleatum* (*P* = 0.73, Mann--Whitney U test). (C) CFU enumeration of *F*. *nucleatum* WT and Ω*siaT* in vaginal washes collected at the indicated time points from Envigo mice. \*\**P* \< 0.01, Mann--Whitney. (D) Time course of vaginal colonization with *F*. *nucleatum* WT and Ω*siaT* mutant in Envigo mice. Percent of mice colonized (*y* axis) was monitored on day 1 and every 2 days thereafter up to 38 dpi (*x* axis). For Kaplan--Meier analysis, mice were considered cleared when no CFUs were detected in undiluted wash at 2 consecutive time points. Statistical significance was assessed by Gehan--Breslow--Wilcoxon test, \**P* \< 0.05. The graphs represent combined data from 2 independent experiments, with 10 mice per group in each experiment. The underlying numerical data for this figure can be found in [S1 Data](#pbio.3000788.s013){ref-type="supplementary-material"}. ATCC, American Type Culture Collection; CFU, colony-forming unit; dpi, days postinoculation; E, estrogenization; IP, intraperitoneal; *siaT*, predicted sialic acid transporter; WT, wild type.](pbio.3000788.g004){#pbio.3000788.g004}

*F*. *nucleatum* enhances sialidase activity in mouse vaginal communities {#sec006}
-------------------------------------------------------------------------

While working with the mouse model, we observed that vaginal sialidase activity waned rapidly after arrival in our facility, both in mice that received mock inoculations ([Fig 5A](#pbio.3000788.g005){ref-type="fig"}) and those inoculated with a different urogenital pathogen such as *E*. *coli* ([S6 Fig](#pbio.3000788.s006){ref-type="supplementary-material"}). In contrast, when inoculated with *F*. *nucleatum*, vaginal sialidase activity was maintained for a significantly longer duration ([Fig 5A](#pbio.3000788.g005){ref-type="fig"}). Additionally, inoculation of WT *F*. *nucleatum* helped to maintain higher levels of vaginal sialidase for a longer duration as compared to inoculation with Ω*siaT* ([Fig 5B](#pbio.3000788.g005){ref-type="fig"}). While sialidase activity was equivalent between WT- and Ω*siaT*-inoculated mice at 1 dpi ([Fig 5C](#pbio.3000788.g005){ref-type="fig"}), by 6 dpi sialidase activity was significantly lower in vaginal washes from mice inoculated with Ω*siaT* compared to WT. These data suggest that besides receiving benefit from the sialidase-producing microbiota, *F*. *nucleatum* also exerts influence of its own by supporting the sialidase-positive vaginal microbiota ([Fig 5D](#pbio.3000788.g005){ref-type="fig"}).

![Microbiota-derived sialidase activity in the mouse vagina is sustained by *F*.*n*. colonization.\
(A) Persistence of sialidase activity in C57BL/6 mice (Envigo) inoculated either with WT *F*.*n*. or vehicle only. Mice were considered sialidase-negative if sialidase activity levels in vaginal washes were below 0.01 μM/min (using the 4MU-Sia assay) for 3 sequential time points. Data are shown from a single experiment with a total of *N* = 20 animals. \**P* \< 0.02, log--rank test. (B--C) Sialidase activity in vaginal washes from 1 to 8 dpi from individual animals purchased from Envigo, estrogenized, and inoculated with either WT or Ω*siaT F*.*n*. The graphs represent combined data from 2 independent experiments, with 10 mice per group in each experiment. Data points with negative values were set to 0.001 to represent them on the log scale. (B) Sialidase activity at later time points were compared to day 1 values using the Friedman test, with correction for multiple planned comparisons using Dunn's test. (C) Same experiment and data as shown in B but analyzed to compare between WT- or Ω*siaT*-inoculated animals at each time point using the Mann--Whitney test. On all graphs, \**P* \< 0.05, \*\**P* \< 0.01, \*\*\*\**P* \< 0.0001. (D) Sialidase producers in the vaginal microbial community release free sialic acids (red diamonds) from host glycoconjugates, providing benefits to *F*.*n*. Hypothesis: at the same time, vaginal community members themselves derive benefits from *F*.*n*., leading to sustained sialidase activity in these communities. Sialidases are represented as scissors. The underlying numerical data for this figure can be found in [S1 Data](#pbio.3000788.s013){ref-type="supplementary-material"}. dpi, days postinoculation; *F*.*n*., *F*. *nucleatum*; *siaT*, predicted sialic acid transporter; WT, wild type; 4MU, 4-methylumbelliferone.](pbio.3000788.g005){#pbio.3000788.g005}

To investigate the effect of *F*. *nucleatum* on sialidase activity produced by vaginal communities in a more reduced system, we investigated the responses of mouse vaginal microbiotas to *F*. *nucleatum* (WT or Ω*siaT*) in an ex vivo anaerobic culture model. As described in the Methods ([Fig 6A](#pbio.3000788.g006){ref-type="fig"} and [S1 Schematic](#pbio.3000788.s009){ref-type="supplementary-material"}), microbial communities generated from vaginal washes of mice were cultured anaerobically in the presence or absence of equal amounts of *F*. *nucleatum* WT or Ω*siaT*, and sialidase activity was measured after overnight culture (approximately 16 h). In cultures from all 4 microbiota pools, those receiving *F*. *nucleatum* (either WT or Ω*siaT*) had significantly higher levels of sialidase activity than the identical microbiota cultured without *F*. *nucleatum* ([Fig 6B](#pbio.3000788.g006){ref-type="fig"}). This assay was performed under nutrient replete conditions in supplemented Columbia media in which WT and Ω*siaT* strains grew equally well, resulting in indistinguishable final colony-forming unit (CFU) titers ([Fig 6C](#pbio.3000788.g006){ref-type="fig"}). Together with the result in [Fig 6B](#pbio.3000788.g006){ref-type="fig"}, this suggests that WT and Ω*siaT*, when present at the same levels, result in similar increases in microbiota-derived sialidase activity. Variation of the starting inoculum of both *F*. *nucleatum* strains revealed a dose-dependent effect on microbiota-derived sialidase activity ([Fig 6D](#pbio.3000788.g006){ref-type="fig"}). These data suggest that in mice, the divergence of sialidase activity in groups receiving WT versus Ω*siaT* arising after 6 days ([Fig 5C](#pbio.3000788.g005){ref-type="fig"}) resulted from different "doses" of *F*. *nucleatum* (arising as of day 3; [Fig 4C](#pbio.3000788.g004){ref-type="fig"} and [S4 Fig](#pbio.3000788.s004){ref-type="supplementary-material"}) rather than a specific feedback loop involving sialic acid catabolism.

![Ex vivo interaction between *F*.*n*. and the mouse vaginal microbiota leads to enhanced sialidase activity.\
(A) Microbiotas from vaginal washes were collected from mice prior to inoculation in [Fig 4B](#pbio.3000788.g004){ref-type="fig"}, pooled (by cage), cultured, and frozen ([S1 Schematic](#pbio.3000788.s009){ref-type="supplementary-material"}, Step 1). Bacteria were recovered from frozen microbiota pools by streaking them on supplemented Columbia blood plates anaerobically and incubating for 24 h at 37°C. Microbial growth was gently scraped from these plates and resuspended in liquid media to prepare OD-normalized inocula and cocultured with *F*.*n*. WT or Ω*siaT* overnight (approximately 16 h). (B) Sialidase activity in microbiota pools from Envigo mice, cultured in the presence or absence of *F*.*n*. Each "microbiota pool" consists of a cultured vaginal community from pooled vaginal wash of 4--5 cohoused mice. Wilcoxon paired-sign rank test was used for pairwise comparison. Data shown are combined from 4 independent biological replicates with 7--8 technical replicates for each microbiota pool. \**P* \< 0.05, \*\**P* \< 0.01. (C) *F*.*n*. titers after overnight growth with microbiota pools from Envigo mice. (D) Dose-dependent boost in sialidase activity in microbiota pools from Envigo mice, cultured in the presence or absence of *F*.*n*. (inocula high to low: OD~600~ 0.10 or 0.025 or no *F*.*n*.). Line in the box indicates median value. Data shown are representative of 3 independent experiments. The underlying numerical data for this figure can be found in [S1 Data](#pbio.3000788.s013){ref-type="supplementary-material"}. CFU, colony-forming unit; *F*.*n*., *F*. *nucleatum*; OD, optical density; *siaT*, predicted sialic acid transporter; WT, wild type.](pbio.3000788.g006){#pbio.3000788.g006}

*F*. *nucleatum* enhances sialidase activity and facilitates growth of *G*. *vaginalis* in human vaginal communities {#sec007}
--------------------------------------------------------------------------------------------------------------------

A significant limitation of using mice to model interactions within the vaginal microbiome is that they have distinctly different vaginal microbiotas compared to humans. Thus, our findings in mice led us to wonder whether *F*. *nucleatum* also leads to increased sialidase activity in human vaginal microbial communities. To test whether *F*. *nucleatum* stimulates sialidase activity in human vaginal microbial communities, vaginal swabs were collected from women, and living bacterial communities were then transported anaerobically to the lab and immediately prepared for viable cryopreservation under anaerobic conditions ([S2 Schematic](#pbio.3000788.s010){ref-type="supplementary-material"}: Step 1). Next, vaginal communities from 21 women who had sialidase activity in their aerobic vaginal swab eluates ([S7 Fig](#pbio.3000788.s007){ref-type="supplementary-material"}) were thawed and cultured anaerobically in the presence or absence of *F*. *nucleatum* ([Fig 7A](#pbio.3000788.g007){ref-type="fig"} and [S2](#pbio.3000788.s010){ref-type="supplementary-material"} Schematic: Step 2). As we observed with mouse microbial communities, human vaginal communities cultured with added *F*. *nucleatum* had significantly higher levels of sialidase activity after culture than the identical community cultured without *F*. *nucleatum* ([Fig 7B](#pbio.3000788.g007){ref-type="fig"}).

![*F*.*n*. supports *Gardnerella* growth and stimulates sialidase activity within human vaginal communities.\
(A--D) Human vaginal communities from 21 individual women were used. (A) Microbial communities were eluted from vaginal swabs under anaerobic conditions in nutrient-rich media. Communities with potential sialidase producers (sialidases are represented as scissors) were cultivated anaerobically in supplemented Columbia media in the presence or absence of added *F*.*n*. (B) Sialidase activity was measured following anaerobic culture. Negative values were set to 0.0018 (lowest positive value) to depict them on the log scale. Graphs show data combined from 2 independent experiments. (C) Relative abundance of *G*.*v*. in cultured human vaginal communities. Sequencing of the gene encoding the V4 region of 16S rRNA was used to estimate proportions of *G*.*v*. in the microbial communities. (D) Quantitation of *G*.*v*. in cultured human vaginal communities by *tuf* qPCR. In each case, statistical comparison between the 2 groups was performed using Wilcoxon matched-pairs signed rank test. The underlying numerical data for this figure can be found in [S1 Data](#pbio.3000788.s013){ref-type="supplementary-material"}. On all graphs, \*\*\**P* \< 0.001, \*\*\*\**P* \< 0.0001. *F*.*n*., *F*. *nucleatum*; *G*.*v*., *G*. *vaginalis*; qPCR, quantitative PCR; *tuf*, Translation elongation factor Tu.](pbio.3000788.g007){#pbio.3000788.g007}

There are at least 2 possible explanations for the enhanced sialidase activity observed upon addition of *F*. *nucleatum* to vaginal communities. First, if *F*. *nucleatum* drives sialidase activity in communities by promoting the growth of sialidase-producing bacteria, it would indicate a mutualistic relationship between *F*. *nucleatum* and sialidase-producing bacteria. Alternatively, *F*. *nucleatum* could induce sialidase expression without promoting growth of sialidase-producing bacteria, which would suggest a commensal or parasitic relationship between *F*. *nucleatum* and sialidase-producing bacteria (depending on whether the latter were unaffected or harmed). *G*. *vaginalis* is believed to be a primary source of sialidase activity in vaginal fluids of women with BV \[[@pbio.3000788.ref031],[@pbio.3000788.ref060]\]. To further investigate the potential benefit of *F*. *nucleatum* to sialidase-producing bacteria, we used community profiling to assess the relative levels and qPCR for absolute quantification of *G*. *vaginalis* in human vaginal communities. Following DNA extraction from vaginal communities cultured with or without *F*. *nucleatum*, we performed community profiling based on the gene encoding the 16S ribosomal subunit (V4 region). When *F*. *nucleatum* was present, *G*. *vaginalis* occupied a significantly larger fraction of the endogenous community compared to identical microbiotas cultured under the same conditions but without *F*. *nucleatum* ([Fig 7C](#pbio.3000788.g007){ref-type="fig"}). Next, we used a previously validated qPCR assay based on the *Gardnerella* Translation elongation factor Tu (*tuf*) gene encoding elongation factor Tu \[[@pbio.3000788.ref061]\], *G*. *vaginalis* was detected at significantly higher levels in communities cultured with *F*. *nucleatum* compared with the same communities cultured without addition of *F*. *nucleatum* ([Fig 7D](#pbio.3000788.g007){ref-type="fig"}). These data strongly suggest that *F*. *nucleatum* supports the development of dysbiotic vaginal communities that become enriched with *Gardnerella* and sialidase activity.

To more specifically study the effect of *F*. *nucleatum* on *G*. *vaginalis*, we established an in vitro coculture system. *G*. *vaginalis* (strain JCP8151B) and *F*. *nucleatum* were coinoculated across a range of inocula doses into supplemented Columbia broth, which is nutrient-rich but inadequate for growth of *G*. *vaginalis*. Cultures in 96-well plates were incubated anaerobically at 37°C overnight. Inoculated alone under these conditions, *G*. *vaginalis* could not be recovered alive ([Fig 8A](#pbio.3000788.g008){ref-type="fig"}, plotted at one-half the detection limit). However, coinoculation with *F*. *nucleatum* resulted in significant growth of *G*. *vaginalis* (\>4 orders of magnitude), which increased further with higher inocula of *F*. *nucleatum*. Experiments using filter-sterilized (cell-free) spent media from cultures of *F*. *nucleatum* revealed a similar boost in *G*. *vaginalis* CFU, suggesting that the *G*. *vaginalis* growth-promoting factor or factors are present in the cell-free supernatant and do not require live bacteria ([Fig 8B](#pbio.3000788.g008){ref-type="fig"}). There was a dose-dependent increase in *G*. *vaginalis* titers with increasing proportions of *F*. *nucleatum* spent supernatant. These data suggest that *F*. *nucleatum* may secrete one or more factors that have a strong growth-promoting effect on *G*. *vaginalis*.

![Enhanced growth of *G*.*v*. in cocultures with *F*.*n*.\
(A) Analysis of *G*.*v*. growth by CFU enumeration in anaerobic cocultures with or without *F*.*n*. in supplemented Columbia medium. Data shown are combined from 2 independent experiments, with 3 technical replicates each. (B) Growth of *G*.*v*. in media with whole *F*.*n*. or spent cell-free supernatant from *F*.*n*. culture. Data shown are combined from 2 independent experiments, with 2 technical replicates each. (C) Dose-dependent effect of *F*.*n*. on *G*.*v*. growth in supplemented Columbia medium. Data shown are combined from 9 independent experiments. Note that at low inocula, *G*.*v*. was not detectable under these conditions in the absence of *F*.*n*. In this case, *G*.*v*. levels were plotted at one-half the LOD (LOD = 200 CFU/mL). For A--C, data are represented in box plot format with whiskers of min and max. Statistical analysis: Kruskal--Wallis followed by Dunn's multiple comparisons test. (D) Sialidase activity in *G*.*v*. cultured overnight with *F*.*n*. WT in supplemented Columbia medium. Heat map data are representative of 2 independent experiments. Inoculum range---*F*.*n*. OD~600~: 0, 0.00625, 0.0125, 0.025, 0.05, 0.1; *G*.*v*. OD~600~: 0, 0.000781, 0.001562, 0.003125, 0.00625, 0.0125, 0.025, 0.05. The underlying numerical data for this figure can be found in [S1 Data](#pbio.3000788.s013){ref-type="supplementary-material"}. On all graphs, \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001. CFU, colony-forming unit; *F*.*n*., *F*. *nucleatum*; *G*.*v*., *G*. *vaginalis*; LOD, limit of detection; n/a, not applicable; OD, optical density; WT, wild type.](pbio.3000788.g008){#pbio.3000788.g008}

Viable recovery of *G*. *vaginalis* in monoculture could also be improved by increasing the dose of the *G*. *vaginalis* inoculum. However, across the entire range of *G*. *vaginalis* inocula used, the addition of *F*. *nucleatum* improved recovery by orders of magnitude (as few as 1, as many as 7; [Fig 8C](#pbio.3000788.g008){ref-type="fig"}). *G*. *vaginalis* viability after overnight incubation in this system required at least a 20,000-fold higher inoculum in monoculture compared to what could be achieved in cocultures with *F*. *nucleatum*. Comparing sialidase activity across a spectrum of *G*. *vaginalis* inocula doses (up to OD~600~ 0.05) revealed no detectable sialidase activity when the organism was grown without *F*. *nucleatum* ([Fig 8D](#pbio.3000788.g008){ref-type="fig"}). Even a relatively small inoculum of *F*. *nucleatum* resulted in measurable sialidase activity in the cultures. Also, sialidase activity could be rescued in cultures inoculated with progressively lower levels of *G*. *vaginalis* by adding higher amounts of *F*. *nucleatum*. As with WT *F*. *nucleatum* ([Fig 8](#pbio.3000788.g008){ref-type="fig"}), dose-dependent increases in sialidase activity were also observed when *G*. *vaginalis* was cocultured with Ω*siaT F*. *nucleatum* ([S8 Fig](#pbio.3000788.s008){ref-type="supplementary-material"}). This is similar to observations made in coculture experiments with mouse vaginal communities in which both WT and Ω*siaT* had similar boosting effects on sialidase activity ([Fig 6B](#pbio.3000788.g006){ref-type="fig"}). These findings further illustrate that the growth benefit to *Gardnerella* is not directly tied to *F*. *nucleatum* sialic acid catabolism. This also suggests that while both *F*. *nucleatum* and *G*. *vaginalis* may benefit from cohabitation, their mutualism is not obligate, but rather facultative. However, in a polymicrobial community with shared and limited nutrient resources, such a relationship could become a necessary tool for survival and persistence.

Discussion {#sec008}
==========

A growing number of literature reports describe the contents and dynamics of the human vaginal microbiome, but we still know surprisingly little about how vaginal dysbiosis develops or why women with BV are more likely to harbor potentially pathogenic vaginal bacteria. One of the prevailing concepts is that an absence of secreted antimicrobial activities produced by "healthy" lactobacilli creates a permissive vaginal environment in which opportunists can overgrow \[[@pbio.3000788.ref007],[@pbio.3000788.ref014],[@pbio.3000788.ref062]\]. Here, we provide evidence for a different type of relationship---a mutualism that actively reinforces new pathogen colonization (*F*. *nucleatum*) while promoting the expansion of features linked with dysbiosis (*G*. *vaginalis*, sialidase). Our analysis of sialic acid catabolism by *F*. *nucleatum* suggests that the presence of sialidase activity in the vagina during BV may allow *F*. *nucleatum* to capitalize on the increased availability of free sialic acid. Additionally, experiments in the mouse model further support the role of sialic acid metabolism in the persistence of *F*. *nucleatum* in a sialidase-positive environment in vivo. We also discovered that a mutually beneficial relationship exists between *F*. *nucleatum* and sialidase-producing bacteria within vaginal microbiomes. Both ex vivo and in vitro coculture studies show that *F*. *nucleatum* can support the outgrowth of *G*. *vaginalis*, one of the most common and abundant species that overgrows in BV, suggesting an important role of interspecies crosstalk in shaping the dynamics of the vaginal microbiome.

Several features of the mouse model, together with considerations of human physiology, have guided our interpretations of the in vivo data. Sialic acid catabolism provided a benefit to *F*. *nucleatum* in specific contexts. However, the organism initially colonized 100% of mice, even in the absence of sialidase, suggesting that sialic acid catabolism is not an absolute requirement for initial *F*. *nucleatum* vaginal colonization in mice. Thus, *F*. *nucleatum* must be using other strategies to colonize the vagina in the sialidase-negative setting. Indeed, the mechanisms of colonization may be distinct in mice from different vendors, in which competition for resources with different microbes may have distinctly different outcomes. Other models of vaginal infection have also yield different results depending on the composition of the endogenous microbiota, as illustrated in a recent study of Group B *Streptococcus* \[[@pbio.3000788.ref063]\]. Furthermore, because of the diverse potential sources of bacterial sialidase, the compositional and physiological complexity of vaginal communities, and insufficient experimental tools for genetic manipulations in many fastidious vaginal anaerobes, we lack precise experimental control of sialidase within bacterial communities. In addition to mutualistic relationships among members of the dysbiotic microbiota, antagonistic interactions probably also impact the vaginal environment in humans. For example, women without BV, who lack sialidase activity, also have lactobacilli that create an environment of high lactic acid and low pH \[[@pbio.3000788.ref020],[@pbio.3000788.ref064]\], which likely contributes to the exclusion of *Fusobacterium*. Together, these considerations provide an overarching rationale that may help explain why *F*. *nucleatum* has been isolated at approximately 6-fold higher rates among women with BV compared to those without (54% versus 9.4%, respectively) \[[@pbio.3000788.ref003]\]. Future studies on the ecology of vaginal microbial communities will be necessary to map and evaluate the magnitude of synergistic and antagonistic interactions connecting species within vaginal communities.

Although it is not known how women acquire vaginal *F*. *nucleatum*, the ubiquitous presence of *F*. *nucleatum* in the mouth points to orovaginal contact as one plausible route of vaginal exposure. Indeed, several studies suggest orogenital contact is a risk factor for BV or vaginal community features consistent with dysbiosis, such as low levels of *Lactobacillus* or high levels of *G*. *vaginalis* \[[@pbio.3000788.ref065]--[@pbio.3000788.ref069]\]. Our data suggest that such exposure could lead to outgrowth of *G*. *vaginalis*, even if *Fusobacteria* are introduced at relatively low numbers. In light of these findings, future studies should evaluate whether exposure of the vagina to microbes from other body sites (for example, oral, rectal, penile) may enhance dysbiotic features of the vaginal microbiome.

*F*. *nucleatum* often cohabitates with sialidase-producing bacteria at mucosal niches such as the oral cavity, gut, and vagina \[[@pbio.3000788.ref042]--[@pbio.3000788.ref046]\]. Thus, our findings also have pertinence for other dysbioses and infections where *Fusobacterium* species have been implicated. For example, *F*. *nucleatum* is a ubiquitous member of the oral microbiome in humans but also overgrows and plays key roles in the multispecies biofilm seen in periodontal disease. Some of the members of this biofilm are also sialidase producers \[[@pbio.3000788.ref070]--[@pbio.3000788.ref072]\]. As observed in BV \[[@pbio.3000788.ref031]\], depletion of sialic acids from the oral mucosa has been observed in gingivitis \[[@pbio.3000788.ref073]\], another condition associated with overgrowth of *F*. *nucleatum*. Additionally, *F*. *nucleatum* has also been identified as a contributor in colorectal cancer \[[@pbio.3000788.ref074]\]. Colorectal tumors that have metastasized to other locations in the body commonly contain not only *F*. *nucleatum* but also species of *Bacteroides*, which are sialidase producers \[[@pbio.3000788.ref075]\]. In fact, sialidase-producing members of the Bacteroidetes often cohabitate with *Fusobacterium* in abscesses, amniotic fluid infections, and polymicrobial bacteremia/sepsis \[[@pbio.3000788.ref076]--[@pbio.3000788.ref080]\]. Together with the data presented here, these findings suggest that *F*. *nucleatum* may benefit from sialidase-producing bacteria during disease processes throughout the human body.

In conclusion, these studies provide the first direct evidence that mutual benefit, made possible in part through metabolite cross-feeding, can promote pathogen colonization of the vagina and encourage features of vaginal dysbiosis. These findings may help explain why women with BV are more likely to be vaginally colonized with potential pathogens linked with intrauterine infection and adverse health outcomes. Although the present work greatly advances our understanding of bacterial relationships that may influence the development of dysbiosis, additional study is needed to apply these principles to the prevention or treatment of dysbiosis in women. Additional investigations of the relationships between vaginal microbes may further reveal the metabolic networks that connect bacterial species within diverse vaginal communities and point to potential target pathways to disrupt these relationships.

Methods {#sec009}
=======

Ethics statement {#sec010}
----------------

Animal research: mouse experiments were carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals. The protocol was approved by the Institutional Animal Care and Use Committee (IACUC) of Washington University School of Medicine (Protocol Number: 20170081).

Human subject research: vaginal specimens collected from women who participated in the Urogenital Community (UC) Bank project, an archive of living microbial communities established for translational microbiome research, were used for these studies, according to Washington University in Saint Louis IRB-approved protocol (protocol number, 20170412; PI, Amanda Lewis). A written informed consent was obtained from all participants enrolled in the UC Bank project. Nonpregnant women seeking care at the North Central Community Health Center, a no-fee clinic operated by the St. Louis County health department, were enrolled in the UC Bank project. While no specific racial or demographic group was sought or excluded for participation, \>90% of women enrolled self-identified as black, a demographic very similar to the community neighboring the clinic. Women with known human immunodeficiency virus or hepatitis C virus or with recent antibiotic use (past 3 weeks) were excluded.

Bacterial strains and growth conditions {#sec011}
---------------------------------------

For a list of bacterial strains, plasmids, and primers, see [S1 Table](#pbio.3000788.s011){ref-type="supplementary-material"}. WT strains of *E*. *coli* (TOP10) \[Invitrogen, Carlsbad, CA, USA\] and MG1655, UTI89, and CFT073 \[provided by Dr. Scott Hultgren\] were grown in lysogeny broth (LB) at 37°C unless otherwise noted. For plasmid maintenance, ampicillin was used at 100 μg/mL and chloramphenicol at 20 μg/mL. Sm^R^ isolate of *G*. *vaginalis* JCP8151B \[[@pbio.3000788.ref031],[@pbio.3000788.ref081]\], hereafter referred to simply as *G*. *vaginalis*, was cultured in NYCIII media containing 10% heat-inactivated horse serum at 37°C in an anaerobic chamber unless stated otherwise. *F*. *nucleatum* strains ATCC25586, ATCC23726, and ATCC10953 were obtained from ATCC (Manassas, VA, USA). Strains JMP2A, FQG51A, JMSY1, JMH52, SYJL4, JM6, and JM4 \[[@pbio.3000788.ref050]\] were provided by Dr. Justin Merritt. ATCC23726 is the primary WT strain background used to model interaction with sialidases and the microbiome. As described below, a spontaneous Sm^R^ mutant of ATCC23726 was isolated and, unless otherwise indicated, was used in all experiments. All fusobacterial strains, unless stated otherwise, were grown at 37°C in an anaerobic chamber in Columbia broth supplemented with hemin (5 μg/mL) and vitamin K3 (1 μg/mL), referred to as "supplemented Columbia" (contains glucose as well as sialoglycans from animal ingredients). For clarity, we have avoided the term "supplemented" to refer to the addition of other components to media. When grown on solid media, supplemented Columbia blood agar plates were used (containing 5% defibrinated laked sheep blood and 1.5% agar). For some experiments, we developed a nutrient-limited media that contains base components present in Columbia media, including proteose peptone \#3 (1% w/v), sodium chloride (0.5% w/v), and HEPES (16.8 mM). Although the requirements of *F*. *nucleatum* do not allow us to do single-carbon--source experiments, this simple medium was used in a similar manner with or without added carbohydrate sources and is referred to throughout the text as "nutrient-limited" media.

Identification of putative sialate lyase (NanA) homologs in *F*. *nucleatum* {#sec012}
----------------------------------------------------------------------------

A sequence similarity search was conducted using the protein blast (BLASTp ver. 2.2.31+) program from the BLAST suite \[[@pbio.3000788.ref082]\]. Amino acid sequences of NanA from *E*. *coli* MG1655 (GenBank: AAC76257.1) and *F*. *nucleatum* subsp. *nucleatum* ATCC23726 (GenBank: EFG95907.1) were used as query to the nonredundant (NR) protein sequences database for *F*. *nucleatum* (taxid: 851). Any hits with an *E*-value less than 1 × 10^−9^ were considered significant.

Free sialic acid foraging by *F*. *nucleatum* {#sec013}
---------------------------------------------

*E*. *coli* (Top 10) was cultured aerobically in LB medium with added sialic acid (Neu5Ac, 100 μM). Fusobacteria ([S1 Table](#pbio.3000788.s011){ref-type="supplementary-material"}) were cultured anaerobically in supplemented Columbia media with added sialic acid (Neu5Ac, 100 μM, A0812; Sigma-Aldrich, St. Louis, MO, USA), which was also used as the uninoculated medium control in this experiment. After 24--48 h of growth, media supernatant was separated from bacterial cells by centrifugation at 15,000 × *g*. In some experiments, collected media supernatant was filtered using a 10,000 molecular weight cutoff (MWCO) filter. Samples were then processed for 1,2-diamino-4,5-methylenedioxybenzene (DMB) derivatization for measurement of free sialic acid (Neu5Ac) remaining in the medium, as described below.

Measurement of total and free sialic acids by DMB-HPLC {#sec014}
------------------------------------------------------

Derivatization and quantitation of sialic acids by HPLC was carried out as previously described \[[@pbio.3000788.ref031],[@pbio.3000788.ref083]--[@pbio.3000788.ref086]\]. Briefly, total sialic acids were measured by first releasing any bound sialic acids using mild acetic acid hydrolysis (2 N acetic acid for 3 h at 80°C), followed by derivatization of total sialic acids with DMB as described below. Alternatively, free sialic acid levels were measured by DMB derivatization without prior acid hydrolysis. The derivatization reaction requires that sialic acids be in the monosaccharide form. Thus, the concentration of bound sialic acids is measured indirectly (bound = total − free). Reaction conditions for DMB derivatization were 7 mM DMB, 22 mM sodium thiosulfite, 0.75 M 2-mercaptoethanol, and 1.4 M acetic acid for 2 h at 50°C. Derivatized samples were injected into a Waters HPLC (Milford, MA, USA) equipped with a reverse-phase C18 column (Tosoh Bioscience, Tokyo, Japan) and eluted using isocratic conditions at 0.9 ml/min using 8% methanol, 7% acetonitrile in water. An online fluorescence detector (Waters) was set to excite at 373 nm and detect emission at 448 nm. Peak integrations were used to quantitate sialic acid content by referencing a standard curve of pure sialic acid (Neu5Ac; Sigma-Aldrich) derivatized in parallel.

Complementation of *E*. *coli* MG1655 sialate lyase mutant *ΔnanA* and growth comparison {#sec015}
----------------------------------------------------------------------------------------

MG1655 *nanA* was amplified with the primers MG1655 nanA F Nco and MG1655 nanA R Pst ([S1 Table](#pbio.3000788.s011){ref-type="supplementary-material"}). The PCR product was desalted, digested with the restriction enzymes NcoI and PstI, and ligated into the NcoI and PstI sites of pTrc99A to create pLR7. *F*. *nucleatum* ATCC23726 *nanA* was amplified with the primers Fuso nanA F Nco and Fuso nanA his R Bam. Following desalting and digestion with NcoI and BamHI, the amplicon was cloned into the same sites in pTrc99A, creating pLR10. The *E*. *coli* MG1655 *ΔnanA* mutant LSR4 was described previously \[[@pbio.3000788.ref036]\]. LSR4 was transformed with pLR7, pLR10, or the vector control (pTrc99A) ([S1 Table](#pbio.3000788.s011){ref-type="supplementary-material"}). The 3 strains were grown to an OD~600~ of 1.0 in LB broth containing 100 μg/mL ampicillin. Then, each strain was diluted 1:100 into M63 media lacking glycerol and with added Neu5Ac (15 mM). The OD~600~ was measured every 10 min at 37°C in a 96-well plate (flat bottom; Greiner Bio-One, Monroe, NC, USA) in a TECAN M200 plate reader with 10 s of orbital shaking at the beginning of each time point.

Sialate lyase assay by complementation of mutant *E*. *coli* {#sec016}
------------------------------------------------------------

The *E*. *coli ΔnanA* mutant (LSR4) containing pLR7 (*E*. *coli* MG1655 *nanA*), pLR10 (*F*. *nucleatum nanA*), or empty vector control (pTrc99A) was grown by shaking at 37°C in 35 mL Circle Grow broth with 100 μg/mL ampicillin to an OD~600~ of 1.0. Cultures were then transferred to room temperature, induced with 0.2 mM IPTG, and grown by shaking overnight. By the next morning, cultures had grown to an OD~600~ of approximately 4.0. Next, 25 ml of each culture was centrifuged at 12,000 × *g* for 10 min, and the cells were resuspended in 800 μL PBS. Cell suspensions were sonicated on ice for 40 s in 1-s bursts at 24% amplitude in a Sonic Dismembrator (Thermo Fisher Scientific, Waltham, MA, USA). Insoluble debris was removed by centrifugation at 15,000 × *g* for 10 min, and 90 μL of each supernatant was mixed with 10 μL of 1 mM Neu5Ac for a final concentration of 100 μM. Mixtures were incubated at 37°C, and at each time point, 10-μL samples were removed, diluted 5× in water, and frozen at −20°C prior to analysis by DMB-HPLC.

Isolation of an Sm^R^ mutant of *F*. *nucleatum* for selective enumeration {#sec017}
--------------------------------------------------------------------------

*F*. *nucleatum* ATCC23726 was cultured anaerobically overnight in supplemented Columbia media at 37°C. Cultured bacteria (20 mL) were pelleted by centrifugation at 16,000 × *g* for 10 min at room temperature, resuspended in 1 mL PBS, and plated on supplemented Columbia blood plates with 1 mg/mL streptomycin sulfate to select for spontaneous Sm^R^ colonies. After 2 days, Sm^R^ colonies from Columbia plates (with strep) were cultured in supplemented Columbia broth. The Sm^R^ strain was used for all experiments with the exception of [Fig 1A](#pbio.3000788.g001){ref-type="fig"}. Mutation of the *rpsL* gene (encoding the ribosomal protein S12) in the *F*. *nucleatum* ATCC23726-Sm^R^ strain was confirmed by colony PCR and DNA sequencing.

Mutagenesis targeting sialic acid consumption via *siaT* in *F*. *nucleatum* ATCC23726 {#sec018}
--------------------------------------------------------------------------------------

Restriction endonucleases, Phusion DNA polymerase, and T4 ligase were obtained from New England Biolabs (Ipswich, MA, USA). First, a suicide vector was constructed using the origin of replication from pUC19 and the chloramphenicol acetyltransferase gene (*catP*) from pJIR418 ([S1 Table](#pbio.3000788.s011){ref-type="supplementary-material"}). Briefly, the origin of replication was amplified from pUC19 using primers pUC19 ori F Sac Kpn Nco and pUC19 ori R Bgl2. The *catP* gene from pJIR418 was amplified with primers catP F Bgl2 and catP R Bam Pst Nco. The 2 amplicons were desalted, digested with NcoI and BglII, and ligated together, resulting in pLR23. A 0.5-kb internal fragment of *F*. *nucleatum siaT* was amplified from ATCC23726 chromosomal DNA with the primers 23726 nan F Nco and 23726 nanR Sac. Following desalting, this PCR product and pLR23 were digested with NcoI and SacI and ligated together, creating pLR25. The Sm^R^ strain of *F*. *nucleatum* ATCC23726 was used as the background for the *siaT* mutation. A starter culture of this strain was diluted 1:1,000 into 10 mL supplemented Columbia broth and grown overnight in the anaerobic chamber at 37°C. Bacteria were then pelleted at 12,000 × *g* for 10 min and washed twice in 1 ml of 1 mM MgCl~2~ containing 10% glycerol. The bacteria were washed twice more in 1 mM MOPS with 20% glycerol and resuspended in 100 μl of the same buffer. Next, 20 μg of purified pLR25 was mixed with the above suspension and incubated on ice for 10 min. The suspension was then transferred to a cuvette with a 0.1-cm gap and electroporated in an Eppendorf Electroporator 2510 (Eppendorf, Enfield, CT, USA) set to 2.5 kV. Bacteria were recovered anaerobically for 5 h in supplemented Columbia broth with added MgCl~2~ (1 mM) at 37°C, then plated on supplemented Columbia agar with 5 μg/mL thiamphenicol. Plasmid integration at the desired locus was confirmed by colony PCR using the primers 23726 nan test F1 and pLR24 5′ F. The mutant strain is referred to as *F*. *nucleatum* Ω*siaT*.

RT-qPCR transcript analysis for genes flanking *siaT* in *F*. *nucleatum* {#sec019}
-------------------------------------------------------------------------

*F*. *nucleatum* WT and *ΩsiaT* were grown anaerobically to exponential phase in supplemented Columbia broth at 37°C. RNA was isolated using PureLink RNA isolation kit (Ambion, Austin, TX, USA) according to the manufacturer's instructions and treated with 2.7 Kunitz units of DNase (Qiagen, Hilden, Germany) per microgram of RNA. cDNA was synthesized using a high-capacity cDNA Reverse Transcription kit (Thermo Fisher Scientific) following the manufacturer's protocol. Expression analysis at transcript level was done by RT-qPCR using Power SYBER Green master mix (Applied Biosystems, Foster City, CA, USA) with 1 ng of cDNA and 300 nM of each forward and reverse primer ([S1 Table](#pbio.3000788.s011){ref-type="supplementary-material"}) in a final volume of 20 μL. Data were analyzed by the ΔΔCt method \[[@pbio.3000788.ref087]\]. Expression of target genes was normalized to the relative expression of *F*. *nucleatum*-specific 16S rRNA \[[@pbio.3000788.ref088]\]. Each experiment was performed in triplicate and repeated 3 times.

Growth comparison of *F*. *nucleatum* WT and Ω*siaT* in Columbia broth {#sec020}
----------------------------------------------------------------------

*F*. *nucleatum* ATCC23726 WT and Ω*siaT* were streaked out on supplemented Columbia blood plates with streptomycin (1 mg/mL) and grown in an anaerobic chamber at 37°C for 24 h. Next day, colonies from the plates were gently scraped off using an inoculating loop and resuspended in supplemented Columbia broth. The OD~600~ of the suspension was checked and adjusted to reach a final starting OD~600~ of 0.10 in fresh media. Media alone or inoculated with *F*. *nucleatum* WT or Ω*siaT* (150 μL /well) was transferred to a clear flat-bottom 96-well plate (Cat. No. 655161; Greiner Bio-One) and sealed with a transparent seal (Cat No. 2978--2100; USA Scientific, Ocala, FL, USA) to maintain anaerobic conditions. Growth was monitored by recording the OD~600~ every 10 min, with 10 s linear shaking (amplitude 3 mm) followed by a 1-min pause at each time point, at 37°C in a TECAN M200 plate reader (Morrisville, NC, USA) for approximately 30 h.

Growth comparison of *F*. *nucleatum* WT and Ω*siaT* in nutrient-limited media {#sec021}
------------------------------------------------------------------------------

Experiments were conducted in a nutrient-limited media containing 1% (w/v) proteose peptone \#3, 0.5% (w/v) sodium chloride, and 16.8 mM HEPES under anaerobic conditions. *F*. *nucleatum* ATCC23726 WT and Ω*siaT* were first cultured overnight anaerobically in supplemented Columbia media. After approximately 16 h, in a clear flat-bottom 96-well plate (Cat. No. 655161; Greiner Bio-One), each strain of *F*. *nucleatum* was inoculated in nutrient-limited media (200 μL/well) containing different added carbohydrate sources as follows: (i) 30 mM glucose, (ii) no added carbon source (low-carbohydrate), (iii) 30 mM Neu5Ac, (iv) 30 mM 3SL (αNeu5Ac2-3βDGal1-4DGlc), and (v) 30 mM 3SL with 50 mU of *A*. *ureafaciens* sialidase. Both strains were inoculated at starting OD~600~ of 0.1, and the plate was sealed with a transparent seal (Cat No. 2978--2100; USA Scientific) to maintain anaerobic conditions. Growth was monitored by recording OD at 600 nm every 10 min, with 10 s linear shaking (amplitude 3 mm) followed by a 1-min pause at each time point at 37°C in a TECAN M200 plate reader for approximately 50 h.

Fluorometric assay for sialidase activity {#sec022}
-----------------------------------------

All sialidase assays were performed in 96-well U-bottom black polypropylene plates (Eppendorf). Plates were sealed with an optical clear film (Cat No. 2978--2100; USA Scientific) and substrate hydrolysis was monitored by measuring fluorescence of 4-methylumbelliferone (4MU) (excitation 365 nm, emission 440 nm) in a TECAN M200 plate reader every 2 min for 1--2 h at 37°C. To test for potential sialidase activity produced by *G*. *vaginalis* and *F*. *nucleatum*, overnight cultures were adjusted to an OD~600~ of 0.5 and 25 μL was mixed with an equal volume of PBS in the plate, followed by the addition of 100 μL Dulbecco's PBS containing 100 μM 4MU-Neu5Ac (4MU-sialic acid; Goldbio, St. Louis, MO, USA). To monitor sialidase activity in mouse vaginal washes, 25 μL of vaginal wash was mixed with 50 μL PBS containing 100 μM 4MU-sialic acid. A standard curve of 4MU in PBS (0--67 μM) was included in parallel to calculate the rate of 4MU-sialic acid hydrolysis by comparison to standards. Rate of 4MU-sialic acid hydrolysis was used to compare sialidase activity in the mouse vaginal washes between different time points or over a period of time. For in vitro experiments examining the effect of *F*. *nucleatum* on cultured mouse/human vaginal specimens or *G*. *vaginalis*, 50 μL of the final culture was mixed with 100 μL sodium acetate buffer (pH 5.5) containing 500 μM 4MU-sialic acid. Similarly, for sialidase activity assays on (uncultured) human vaginal specimens, 50 μL of resuspended swab eluates was transferred to the plate and mixed with 100 μL sodium acetate buffer (pH 5.5) containing 500 μM 4MU-sialic acid. 4MU in sodium acetate buffer (0--300 μM) was used as a standard in sialidase assays with vaginal swab eluates.

Foraging of sialic acids from bound sialoglycans in nutrient-limited media by *F*. *nucleatum* in the presence or absence of exogenous sialidase {#sec023}
------------------------------------------------------------------------------------------------------------------------------------------------

*F*. *nucleatum* WT and Ω*siaT* were cultured in nutrient-limited media containing 3SL with or without *A*. *ureafaciens* sialidase, as described above. At the end of the growth experiment, 96-well plates were centrifuged at 3,000 × *g* for 20 min at 4°C to separate the media from bacterial cells. Thereafter, spent supernatant from each growth condition (approximately 150 μL/well) was transferred to 0.2-μm 96-well filter plates (Pall Corporation, Port Washington, New York, USA) stacked onto a v-bottom 96-well collection plate (Eppendorf) and centrifuged at 3,000 × *g* for 15 min at 4°C. Total and free sialic acids remaining in the filtered supernatants were measured by DMB labeling as described earlier.

Mouse vendor information, housing conditions, and general handling procedures {#sec024}
-----------------------------------------------------------------------------

For experiments with *F*. *nucleatum*, female C57BL/6 mice (6--7 weeks old) were obtained from Jackson Labs (Bar Harbor facility, MA, USA) and Envigo (202-A Indianapolis facility, IN, USA). Mice were received between January 2016 and January 2017. For experiments testing vaginal sialidase activity among different mouse vendors, female C57BL/6 mice were also obtained from Charles River (NCI Grantee, Frederick facility, MD, USA) and Taconic. Once received at Washington University, mice were housed in a barrier facility kept at 70 ± 2°F, with a 12:12 light/dark cycle, and using corncob bedding, PicoLab Rodent Diet 20, and nestlets for enrichment changed at least once per week. During initial experiments, mice were housed in standard (nonventilated) microisolator cages. Later, our animal facility changed to a new housing system in which larger cages are docked in HEPA-filtered ventilation racks that provide airflow control. Mice were allowed to rest for approximately 1 week prior to the commencement of procedures. Mice were estrogenized as indicated in figure legends by intraperitoneal injection under isofluorane anesthesia with 0.5 mg β-estradiol 17-valerate (E1631; Sigma-Aldrich) in 100 μL filter-sterilized sesame oil. Vaginal washes were collected from isoflurane-anesthetized animals by gently inserting a pipette tip with 50 μL of sterile Dulbecco's PBS approximately 2--5 mm into the vagina and pipetting up and down.

Mouse model of vaginal colonization with *F*. *nucleatum* {#sec025}
---------------------------------------------------------

Our spontaneous Sm^R^ isolate derived from ATCC23726, which we refer to simply as WT *F*. *nucleatum*, was vital to these experiments because it allows us to distinguish inoculated *F*. *nucleatum* from endogenous members of the microbiota for enumeration of CFUs. The Ω*siaT* strain described earlier was derived from this Sm^R^ WT strain. Mice were injected twice with β-estradiol (see above) 3 days prior to and on the day of inoculation, with all animals receiving the first dose approximately 1 week postarrival. To compare the vaginal colonization of *F*. *nucleatum* WT versus Ω*siaT*, a total of 80 mice (40 mice from each vendor) were used in 2 independent experiments, conducted approximately 1 year apart, with each individual experiment including 20 mice from Envigo Labs and 20 from Jackson Labs. Ten mice per vendor were vaginally colonized with *F*. *nucleatum* WT and 10 with the *F*. *nucleatum* Ω*siaT*. To prepare the *F*. *nucleatum* inoculum, the overnight culture was adjusted to an OD~600~ of 4.0 in supplemented Columbia broth and aliquoted in 1.5 mL Eppendorf tubes (25 μL/ tube) for each individual mouse. Mice were vaginally inoculated with approximately 10^8^ CFUs of WT or Ω*siaT* mutant in 20 μL supplemented Columbia broth using a separate aliquot of inoculum for each mouse. In a separate experiment to compare persistence of sialidase activity, Envigo mice were either mock treated by inoculating with supplemented Columbia broth (vehicle) or WT *F*. *nucleatum* in supplemented Columbia broth (*n* = 10 per group). Vaginal washes were collected every 2--3 days, and mice were considered sialidase-negative as of the first of 3 sequential time points in which sialidase activity levels in vaginal washes were below 0.01 μM/min using the 4MU-Sia assay.

Vaginal washes were collected one day before estradiol was first administered, after estrogenization (on the day of inoculation), and then 3 times per week (on alternate days) until 38 dpi or 44 dpi (for mock versus *F*. *nucleatum*). Mice were considered "cleared" of *F*. *nucleatum* when 2 consecutive washes were negative for *F*. *nucleatum* CFUs. Once cleared, mice did not reacquire *F*. *nucleatum*, even if cohoused with colonized mice. Washes were collected from all mice by flushing vaginas with 50 μL sterile PBS and rinsing into an additional 20 μL PBS in a sterile 1.5-mL Eppendorf tube. All washes were collected (from 40 mice) within 1 h and cycled into the anaerobic chamber for CFU enumeration. *F*. *nucleatum* titers were determined from washes by preparing 10-fold serial dilutions in PBS and spotting 5 μL of each dilution in quadruplicate onto supplemented Columbia selection plates with 1 mg/mL streptomycin. After anaerobic incubation at 37°C, colonies were then enumerated and reported as recovered CFU per mL of vaginal fluid. Sialidase activity was measured in freshly collected mouse vaginal washes as described earlier. At appropriate experimental endpoints, mice were sacrificed by cervical dislocation under isoflurane anesthesia or by using carbon dioxide at 10%--30% chamber volume displacement per min using a SmartBox.

Ex vivo mouse vaginal community cultures {#sec026}
----------------------------------------

Mouse vaginal wash material remaining after sialidase assays and *F*. *nucleatum* CFU analysis was pooled by cage (5 mice per cage) for each vendor or treatment condition. A small portion (5 μL) of each pooled vaginal wash sample was used as inoculum to culture the vaginal bacterial communities in supplemented Columbia broth under anaerobic conditions. We refer to these vaginal communities as "microbiota pools." Each microbiota pool represents either uncultured pooled vaginal wash or cultured bacterial community from pooled vaginal wash of mice cohoused in the same cage. The cultured communities (first passage) were frozen with 20% glycerol after overnight growth. Remaining pooled vaginal washes were stored at −20°C for later microbiome studies (see below). See also [S1 Schematic](#pbio.3000788.s009){ref-type="supplementary-material"}.

*F*. *nucleatum*'s influence on sialidase activity in mouse vaginal communities {#sec027}
-------------------------------------------------------------------------------

Experiments were done with microbial communities cultured using pooled vaginal wash specimens (referred to as "microbiota pools") collected from both Envigo and Jackson mice after estrogenization but before inoculation with *F*. *nucleatum*. These experiments were done in Columbia broth, a culture medium that contains sialoglycans from animal ingredients, but these remain inaccessible to *F*. *nucleatum* because of lack of sialidase activity. Cultured mouse vaginal communities (first passage) frozen in Columbia media were streaked out on Columbia blood plates and grown in an anaerobic chamber at 37°C (second passage). After 2 days, Columbia blood plates were gently scraped using an inoculating loop, and bacteria were resuspended in supplemented Columbia broth. The OD~600~ of the suspension was checked and adjusted to 0.5 for the vaginal communities and 1.0 for both *F*. *nucleatum* strains. Experiments were done in v-bottom, 96-well, sterile, deep-well (2-mL) plates (Eppendorf). *F*. *nucleatum* WT or *ΩsiaT* was added in equal amounts to 700 μL (total volume of media per well) of Columbia broth at a starting OD~600~ of either 0.10 or 0.025, followed by addition of vaginal communities at starting OD~600~ 0.05. Appropriate controls such as uninoculated Columbia broth, Columbia broth inoculated with *F*. *nucleatum* alone at a starting OD~600~ of 0.10, and Columbia broth inoculated with each individual vaginal microbial community alone were included in each experiment. After the addition of aluminum foil seals (Product ID: BK538619; Beckman Coulter Life Sciences, Indianapolis, IN, USA), plates were incubated O/N (approximately 16 h) at 37°C in the anaerobic chamber. After O/N growth (third passage of mouse communities), sialidase activity was checked in each well using the fluorometric sialidase assay as described earlier in the Methods. Also, growth of *F*. *nucleatum* WT and *ΩsiaT* with the microbiota pools was determined at this point by preparing 10-fold serial dilutions of the O/N cultures in PBS and spotting 5 μL of each dilution onto Columbia selection plates containing 1 mg/mL streptomycin and 5 mg/L of crystal violet. Microbiota pools cultured without *F*. *nucleatum* did not show any growth on these plates (crystal violet selects against gram-positive bacteria), thus allowing selective enumeration of *F*. *nucleatum* in the cocultures. See also [S1 Schematic](#pbio.3000788.s009){ref-type="supplementary-material"}.

DNA extraction and community profiling of mouse vaginal washes {#sec028}
--------------------------------------------------------------

For microbiome analysis by 16S sequencing, pooled vaginal washes (uncultured microbiotas) from 8 different cages (4 for each vendor, 1 specimen per cage) were centrifuged at 16,000 × *g* for 5 min, the supernatant was removed, and the pellet was used for DNA extraction. For cultured vaginal communities (4 for each vendor, 1 specimen per cage), communities frozen in supplemented Columbia broth were streaked out on supplemented Columbia blood plates and grown overnight at 37°C in an anaerobic chamber (second passage). Colonies from plates were gently scraped off using a cell scraper and resuspended in supplemented Columbia broth. For DNA extraction, bacterial cells from these communities were separated from the supernatant by centrifugation at 16,000 × *g* for 5 min. DNA was extracted using the Wizard Genomic DNA Purification kit from Promega (Cat. No. A1120; Madison, WI, USA) following supplier instructions. See also [S1 Schematic](#pbio.3000788.s009){ref-type="supplementary-material"}.

Mouse vaginal community analysis by V1--V2 sequencing of the 16S rRNA gene {#sec029}
--------------------------------------------------------------------------

For the mouse microbiome experiments, we decided to use the 16S V1--V2 regions after doing a preliminary experiment using the 16S V4 region, which was unable to identify and distinguish members of the *Lactobacillales* down to the species level (for example, *E*. *faecalis* and *E*. *casseliflavus*/*gallinarum*). We amplified the V1--V2 region of the 16S ribosomal subunit with the universal 27F and 338R primers \[[@pbio.3000788.ref004]\]. Both the primers contained a common adaptor sequence and the forward primer also contained a barcode sequence for multiplexing. The primers were as follows: 338R-5′-AGACGTGTGCTCTTCCGATCTCAT**GCTGCCTCCCGTAGGAGT**-3′ and 27F-5′-ACGACGCTCTTCCGATCTNNNNNNNNCT**AGAGTTTGATCCTGGCTCAG**-3′, with the bolded sequences denoting the universal primers and 8-bp barcode being denoted by 8 Ns. After the V1--V2 region was amplified using the 27F and 338R primer pair, the PCR product was treated with Exo-SAP-IT to remove primers. A second PCR was performed to add unique indexes for further multiplexing. The subsequent amplicons were quantified and pooled. The pool was run on a 0.8% agarose gel, excised, and extracted. Agencourt AMPure XP beads (Beckman Coulter Life Sciences) were used for further size selection and purification. The 2 × 150 paired-end sequencing was completed using the Illumina MiniSeq platform (San Diego, CA, USA) through the Center for Genome Science at Washington University School of Medicine. Reads were trimmed for adaptor sequences using ea-utils fastq-mcf version 1.04.676 and de-multiplexed based on the unique barcode and index identifiers. USEARCH \[[@pbio.3000788.ref089]\] version 10.0.240 was used for the following USEARCH commands: (i) reads were merged using the fastq_mergepairs command and (ii) quality filtered with a maximum expected error of 1 and a minimum sequence length of 100 using the fastq_filter command, (iii) merged reads were then dereplicated using the fastx_uniques command, and (iv) OTUs were clustered using the cluster_otus command (97% OTU clustering using UPARSE-OTU algorithm) or unoise3 command (UNOISE algorithm also performs denoising of amplicon reads). As part of the cluster_otus and unoise3 commands, chimeric sequences were filtered out and discarded, and a minimum abundance of 2 reads per OTU was applied. OTUs were assigned taxonomic predictions using the RDP 16S database (version 16) with a confidence threshold of 0.7. For normalization, samples were rarified to 1,000 reads per sample. To quantify relative abundance of each OTU in a given sample, OTU reads were log transformed using the following equation: log(\[reads + 1\]/total reads). All OTUs at \>1% relative abundance in at least one sample were included in analysis. Data were clustered using hierarchical Euclidean clustering in the R project for statistical computing. As in other microbiome studies, sampling methods and primer choice could bias the types of microbes recovered and detected. These limitations may apply to the vaginal microbiome in mice as well as in women.

Mouse model of vaginal inoculation with *E*. *coli* {#sec030}
---------------------------------------------------

Female C57BL/6 mice, 5--7 weeks old, were obtained from Envigo (202-A Indianapolis facility). At 48 and 24 h prior to infection, mice underwent intraperitoneal injections of 0.5 mg β-estradiol 17-valerate (Sigma-Aldrich) in 100 μl filter-sterilized sesame oil (Thermo Fisher Scientific) to synchronize the mice in estrus. Mice were infected with model uropathogenic *E*. *coli* strains (UTI89 and CFT073 \[[@pbio.3000788.ref090],[@pbio.3000788.ref091]\]) or mutant derivatives thereof. Strains were cultured statically in lysogeny broth (LB) at 37°C for 2 consecutive overnight passages. At the time of infection, 10^4^ CFUs of each *E*. *coli* strain were inoculated into the vaginas in 20-μl volumes of PBS. To monitor infection and sialidase status, vaginal washes were collected as described above, serially diluted, and plated on MacConkey agar (titers of these uropathogenic strains went up to approximately 10^8^ CFUs by 24 hpi) \[[@pbio.3000788.ref059]\]. Sialidase activity was measured in freshly collected mouse vaginal washes as described above.

Study design for human subject research {#sec031}
---------------------------------------

To test our hypothesis that sialidase activity would significantly increase in living communities cultured with *F*. *nucleatum* compared with identical communities exposed only to vehicle, our experimental design required that some detectable level of sialidase be present within the microbiome of tested communities. Sialidase activity was measured in 51 available (standard aerobic) swab specimens, of which approximately 60% were sialidase-positive. For the power calculation, our primary outcome was sialidase activity after overnight culture of cryogenically preserved living communities. The exact Agresti--Coull method was used to estimate the sample size needed for the ex vivo studies. To achieve 80%--90% power (alpha = 0.05) to detect sialidase altered in 80% of samples (versus the theoretical random distribution of sialidase levels, which would give 50% of samples with higher sialidase activity in the treatment group), we calculated that we would need 22--28 independent communities. Our experimental design in 96-well plates using different inocula of *F*. *nucleatum* allowed us to evaluate a total of 21 communities in 2 independent experiments (11 communities in the first experiment and 10 communities + 1 duplicate community in the second). There was good agreement between the data for the community that was evaluated in duplicate. Combined data from both experiments are shown (each data point represents a community from 1 individual). Further measurements of *G*. *vaginalis* levels (by qPCR and proportions within the postculture communities) were performed as described in the Methods below.

Collection and processing of human vaginal swabs {#sec032}
------------------------------------------------

Midvaginal swabs were collected during speculum exam by a clinician, immediately submerged into prereduced Cary Blair media using Starswab Anaerobic Transport System S120D (Starplex Scientific, Ontario, Canada), and transported to the laboratory for same-day processing. Once transported anaerobically to the lab, vaginal swabs were cycled into the anaerobic chamber immediately. Swabs were eluted in 2× NYCIII media without glucose, and "fresh-frozen" (i.e., "0 passage," without growth or amplification of any kind) in the presence of sterile glycerol (20% final). In parallel with clinical specimens returning to the lab in anaerobic transport devices, control swabs exposed to the air in clinic exam rooms were also transported anaerobically to the lab and processed in parallel with clinical specimens. Standard (aerobic) double-headed rayon swabs S09D (Starplex Scientific) collected at the same visit were eluted in 1 mL of pH 5.5 sodium acetate buffer, and sialidase activity was measured as described earlier in the Methods. For coculture experiments with *F*. *nucleatum*, we selected anaerobic fresh-frozen vaginal microbial communities from women whose aerobic vaginal swab eluates had detectable sialidase activity ([S7 Fig](#pbio.3000788.s007){ref-type="supplementary-material"}). Fresh-frozen communities from 21 sialidase-positive women were used. See also [S2 Schematic](#pbio.3000788.s010){ref-type="supplementary-material"}.

Ex vivo studies of human vaginal communities {#sec033}
--------------------------------------------

*F*. *nucleatum* ATCC23726 WT was streaked out on supplemented Columbia blood plates and grown in an anaerobic chamber at 37°C for 24 h. The next day, *F*. *nucleatum* colonies from plates were gently scraped off using an inoculating loop and resuspended in supplemented Columbia broth. The OD~600~ of the suspension of *F*. *nucleatum* was adjusted to 1.0. Then, *F*. *nucleatum* inocula were prepared by 2-fold serial dilution in supplemented Columbia media. Fresh-frozen (passage 0) human vaginal communities (*N* = 21) were thawed on ice and diluted 4-fold in 1× NYCIII with no added glucose (low-carbohydrate medium). Experiments were done in v-bottom, 96-well, sterile, deep-well (2-mL) plates (Cat. No. 951033502; Eppendorf). *F*. *nucleatum* was inoculated at a starting OD~600~ of 0.10, followed by addition of 116 μL of the diluted fresh-frozen community in a total of 700 μL media (supplemented Columbia broth) per well. Mock vaginal communities were included as controls in each experiment; these mock communities were originally prepared from blank swabs that were eluted and stored using the same media and reagents, in parallel with swabs returning from the clinic. The plates were sealed with a sealing aluminum foil (Product ID: BK538619; Beckman Coulter) and incubated overnight (17 h) at 37°C in the anaerobic chamber. After overnight growth (first passage of human communities), 50 μL of culture from each condition was transferred to round-bottom black plates, and sialidase activity was measured in each well using the fluorometric sialidase assay as described earlier in the Methods. The 96-well plates with the remaining cultures were centrifuged at 3,200 × *g* for 20 min at 4°C, and supernatants were removed carefully without touching the bacterial cell pellets at the center of the well and stored at −80°C for DNA extraction and PCR as described below. See also [S2 Schematic](#pbio.3000788.s010){ref-type="supplementary-material"}.

DNA extraction from ex vivo-cultivated human vaginal communities {#sec034}
----------------------------------------------------------------

DNA was extracted from bacterial cell pellets, saved from the *F*. *nucleatum* human vaginal communities coculture experiments described above, by bead beating followed by phenol chloroform extraction. Briefly, a 96-well (deep-well, v-bottom) plate with bacterial pellets was thawed, and cells were resuspended in 250 μL of buffer containing 200 mM Tris-HCl (pH 8.0), 200 mM NaCl, and 20 mM EDTA. This suspension was transferred to sterile 2-mL tubes (Axygen, Corning, NY, USA) containing approximately 250 μL silica beads and 105 μL 20% SDS, followed by addition of 250 μL phenol/chloroform/isoamyl alcohol saturated with 10 mM Tris (pH 8.0). After bead beating for 3 min, tubes were centrifuged at 3,200 × *g* for 4 min, and the crude DNA was transferred to clean up columns (Qiagen). Concentration of the purified DNA was determined using Quant-iT BR dsDNA Assay Kit (Thermo Fisher Scientific). Before PCR, DNA was normalized to 2.5 ng/μL for each condition.

16S profiling of ex vivo-cultivated human vaginal communities {#sec035}
-------------------------------------------------------------

16S rRNA PCR was performed in triplicate for each template using Platinum Taq DNA Polymerase, High Fidelity (Thermo Fisher Scientific) using barcoded V4-specific primers as previously described \[[@pbio.3000788.ref092]\]. No-template controls were additionally run with every barcoded primer to ensure that reactions were free from contamination. Replicate PCR reactions were combined and then quantitated using Qubit dsDNA Broad Range Assay reagents (Invitrogen, Waltham, MA, USA). Quantitated DNA V4 16S reactions were then pooled into a single library in an equimolar ratio using the epMotion 5075 TMX (Eppendorf, Hamburg Germany). V4 16S rRNA amplicon libraries were then sequenced on an Illumina MiSeq instrument using 2 × 250 base pair chemistry. Amplicon sequence variants were generated from the de-multiplexed data using the large-data--adapted pipeline for DADA2 version 1.10.1 in R (<https://benjjneb.github.io/dada2/bigdata.html>) \[[@pbio.3000788.ref093]\]. The forward and reverse reads were trimmed to 230 base pairs and 160 base pairs, respectively, based on the average quality profile of forward and reverse reads. Sequences with more than 2 likely erroneous bases or any ambiguous bases were then filtered out. Sequencing errors were learned and amplicons were then de-replicated and partitioned into amplicon sequence variants as described \[[@pbio.3000788.ref093]\]. Forward and reverse reads were subsequently merged, and chimeras were removed. Amplicon sequence variant sequences were assigned taxonomy from kingdom to species using the DADA2 inbuilt function for the naïve Bayesian Classifier \[[@pbio.3000788.ref094]\] with a custom database \[[@pbio.3000788.ref095]\] and a minimum bootstrap support of 80%. For data shown in [Fig 7C](#pbio.3000788.g007){ref-type="fig"}, we excluded the reads for *F*. *nucleatum* ATCC23726 (added exogenously) when determining the total reads to calculate relative levels of *G*. *vaginalis*. Some samples were excluded from the final analysis that had insufficient numbers of reads (0) mapping to *G*. *vaginalis* in either of the conditions tested.

Cloning the *tuf* gene from *G*. *vaginalis* {#sec036}
--------------------------------------------

The primer pair Gvag_tuf_AS3/Gvag_tuf_S4 was used to amplify a 149-bp fragment from the *tuf* gene (GI:311114364) of *G*. *vaginalis* strain JCP8481B. The PCR product was purified using the Nucleospin Gel and PCR Clean-Up Kit (Clontech, Takara Bio, Mountain View, CA, USA) and cloned into the Zero Blunt TOPO vector (Invitrogen) according to the manufacturer\'s instructions.

Quantification of *G*. *vaginalis* by *tuf* qPCR {#sec037}
------------------------------------------------

DNA was extracted from human vaginal communities cultured with/without *F*. *nucleatum* as described above. qPCR was performed using PowerUp SYBR Green Master Mix (Applied Biosystems) with 5 ng of DNA and 250 nM of *tuf* forward and reverse (Gvag_tuf_AS3/Gvag_tuf_S4) primers in a final volume of 20 μL. Plasmid containing a 149-bp fragment of *tuf* gene from *G*. *vaginalis* was employed to generate a standard curve for quantitation. Three replicates were included for each experimental condition, including the no-template control, DNA derived from media-only controls, and blank swab controls. The average CT values from the triplicate reactions were used to calculate the *tuf* copy numbers using the linear equation derived from the standard curve. No-template controls, media-only controls, and blank swab controls fell outside the standard curve (less than 800 copies). *G*. *vaginalis* levels are expressed as *tuf* gene copies per community.

Coculture experiments with *Fusobacterium* and *G*. *vaginalis* {#sec038}
---------------------------------------------------------------

Coculture experiments were done in v-bottom, 96-well, sterile, deep-well (2 mL) plates (Eppendorf). *F*. *nucleatum* ATCC23726 (WT or Ω*siaT*) and *G*. *vaginalis* JCP8151B (Sm^R^) were streaked out on supplemented Columbia blood plates and NYCIII plates with streptomycin (1 mg/mL), respectively, and grown in anaerobic chamber at 37°C for 24 h. The next day, colonies from the plates were gently scraped off using an inoculating loop and resuspended in supplemented Columbia broth. For experiments measuring sialidase activity in the coculture, the OD~600~ of the suspension was checked and adjusted to 0.05 (1.20 × 10^8^ CFU/mL) for *G*. *vaginalis* and 0.1 for *F*. *nucleatum* (WT, 1.80 × 10^8^ CFU/mL; Ω*siaT*, 2.20 × 10^8^ CFU/mL). A series of inocula were prepared for each strain by 2-fold serial dilution. For coculture, prepared inocula for both *F*. *nucleatum* and *G*. *vaginalis* were diluted 10-fold in a total of 700 μL of supplemented Columbia broth per well. The plate was sealed with a sealing aluminum foil (Beckman Coulter) and incubated overnight (17 h) at 37°C in the anaerobic chamber. After overnight growth, sialidase activity was measured in each well using the fluorometric sialidase assay as described earlier. *G*. *vaginalis* titers were determined after overnight growth for a subset of the wells ([Fig 8A](#pbio.3000788.g008){ref-type="fig"}, *G*. *vaginalis* inoculum 2.28 × 10^5^ CFU/mL), with and without WT *F*. *nucleatum* (at the indicated inoculum OD), by preparing 10-fold serial dilutions in PBS (in the anaerobic chamber) and spotting 5 μL of each dilution in quadruplicate onto NYCIII plates containing 1 mg/ml streptomycin, 10 μg/ml colistin, and 10 μg/ml nalidixic acid (colistin and nalidixic acid select against gram-negative bacteria and allow the specific enumeration of *G*. *vaginalis* in this assay). In separate experiments, *G*. *vaginalis* was cocultured with or without *F*. *nucleatum* (inoculum OD~600~ 0.10) at varying inocula, with the highest *G*. *vaginalis* inoculum tested having OD~600~ 1.3 (1 × 10^9^ CFU/mL), and titers were determined after overnight growth as described above.

Experiments with *F*. *nucleatum* cell-free supernatants {#sec039}
--------------------------------------------------------

Preparation of cell-free supernatants: *F*. *nucleatum* WT inoculum was prepared as described earlier. A 10 mL culture was started in supplemented Columbia broth at OD~600~ 0.01 (2.8 × 10^7^ CFU/mL of *F*. *nucleatum*). After overnight growth (approximately 18 hr), bacterial cells were pelleted by centrifugation at 12,000 × *g* for 10 min, and the supernatant was transferred to a new tube. A second centrifugation step was included (12,000 × *g* for 10 min) to remove any remaining bacterial cells, and the supernatant was subsequently filtered through a 0.22-μm membrane to obtain cell-free spent media. These filtered supernatants were spread plated on supplemented Columbia agar and incubated at 37°C for 2 days (no live bacteria were recovered, LOD = 10 CFU/ml). The cell-free supernatant was cycled in the anaerobic chamber at least 4 h before inoculation with *G*. *vaginalis*.

Growth of *G*. *vaginalis* in cell-free supernatants from *F*. *nucleatum*: Experiments were done in v-bottom, 96-well, sterile, deep-well (2-mL) plates (Cat. No. 951033502; Eppendorf). Inocula of *G*. *vaginalis* (3.0 × 10^5^ CFU/mL) and *F*. *nucleatum* (OD~600~ 0.1, 2.5 × 10^8^ CFU/mL) were prepared from colonies on solid-media plates (after 24 h growth) as described above. The inoculum was diluted 10-fold in supplemented Columbia broth with or without cell-free supernatants in a final volume of 700 μL medium per well. The plate was sealed and incubated overnight (approximately 18 h) at 37°C in the anaerobic chamber. After overnight growth, CFUs were enumerated by 10-fold serial dilutions in PBS as described above.

Statistical analysis {#sec040}
--------------------

R project for statistical computing was used for hierarchical clustering of microbiome data. GraphPad Prism 7.0 software was used for all statistical analyses presented. The statistical tests used to analyze each set of data and the number of replicates or independent experiments are indicated in the figure legends. For animal experiments, the figures with titers or sialidase activity show individual data, with each data point representing a value from a different animal with a line at the median. For experiments with human vaginal communities, each data point represents a vaginal community from an individual woman. For nonparametric analyses, differences between the experimental groups were analyzed with a two-tailed unpaired Mann--Whitney U test, or, when making multiple comparisons, we used Dunn's test. In the experiments in which data sets are paired, differences were analyzed using Wilcoxon matched-pairs sign rank test. Survival analysis was done using the Gehan--Breslow--Wilcoxon test.

Supporting information {#sec041}
======================

###### A subgroup of *F. nucleatum* strains encode putative sialate lyase (NanA) homologs.

\(A\) Heat map showing percent identity of NanA homologs in sequenced F. nucleatum strains to the amino acid sequence of sialic acid lyase of E. coli MG1655. Homologs showed high similarity to amino acid sequence of lyase from F. nucleatum ATCC23726. ATCC, American Type Culture Collection; NanA, N-acetylneuraminate lyase.

(TIFF)

###### 

Click here for additional data file.

###### Growth of *F. nucleatum* in supplemented Columbia media.

\(A\) F. nucleatum WT and ΩsiaT show similar growth when cultured anaerobically under these culture conditions. Data shown are representative of 3 independent experiments. siaT, predicted sialic acid transporter; WT, wild type.

(TIFF)

###### 

Click here for additional data file.

###### C57BL/6 mice from Envigo have endogenous vaginal sialidase activity.

\(A\) Sialidase activity in vaginal washes of mice (not estrogenized) from different vendors measured using the fluorogenic 4MU-Neu5Ac substrate. *N* = 10 mice/vendor. (B) Vaginal sialidase activity is elevated at 72 h postestrogenization in mice from Envigo. No sialidase activity was detected in vaginal washes of mice from Jackson. *N* = 40 mice/vendor. Wilcoxon paired-sign rank test was used for pairwise comparison. \*\**P* \< 0.01. (C) Sialidase activity in microbiota pools from Envigo and Jackson mice, collected after estrogenization. Each "microbiota pool" consists of a cultured vaginal community from pooled vaginal washes of 4--5 cohoused mice. For A, B, and C, data shown are combined from 2 independent biological replicates. (D) Heat map shows relative abundance of bacterial taxa identified by 16S rRNA V1--V2 sequencing in vaginal specimens of Envigo and Jackson mice collected before and after estrogenization. Microbiome analysis was done on uncultured and cultured vaginal washes pooled from 5 mice housed in the same cage. Each column represents 1 pool = 1 cage = 5 mice. Total = 4 microbiota pools per vendor per condition. OTUs were clustered using UPARSE-OTU algorithm, and taxonomic predictions were assigned using the RDP 16S rRNA database. (E) For identification of sialidase-positive bacteria in Envigo mice, frozen microbiota pools were streaked on supplemented Columbia blood plates anaerobically incubating for 24 h at 37°C. Single colonies were gently picked from these plates and cultured overnight. (F) Sialidase-positive cultures were identified using 4MU-Sia assay. Strains were identified by amplification and sequencing of 16S gene. Percent identity to the recovered blast hits is given in parentheses. The underlying numerical data for this figure can be found in [S1 Data](#pbio.3000788.s013){ref-type="supplementary-material"} and [S2](#pbio.3000788.s014){ref-type="supplementary-material"} Data. Neu5Ac, *N*-acetylneuraminic acid; OTU, Operational Taxonomic Unit; RDP, Ribosomal Database Project; 4MU, 4-methylumbelliferone.

(TIFF)

###### 

Click here for additional data file.

###### *Fusobacterium* vaginal colonization and sialic acid foraging in C57BL/6 mice from Envigo inoculated with *F*. *nucleatum* WT and Ω*siaT*.

\(A\) *F*. *nucleatum* titers in vaginal wash collected at the indicated time points postinoculation. Data are combined from 2 independent experiments. Each experiment had 10 mice per group. \**P* \< 0.05, \*\**P* \< 0.01, Mann--Whitney. (B) Free and total sialic acid (Neu5Ac) concentrations in vaginal wash at 8 dpi. Total *N* = 18. The underlying numerical data for this figure can be found in [S1 Data](#pbio.3000788.s013){ref-type="supplementary-material"}. dpi, days postinoculation; *N*-acetylneuraminic acid; *siaT*, predicted sialic acid transporter; WT, wild type.

(TIFF)

###### 

Click here for additional data file.

###### *F*. *nucleatum* WT and Ω*siaT* vaginal colonization in C57BL/6 mice from Jackson.

\(A\) *F*. *nucleatum* titers in vaginal wash collected at the indicated time points postinoculation. (B) Comparison of vaginal colonization with the WT versus Ω*siaT*. Number of mice colonized in percent (*y* axis) was monitored on day 1 and every 2 days thereafter for 38 days (*x* axis). For Kaplan--Meier analysis, mice were considered cleared when no CFUs were detected in undiluted wash at 2 consecutive time points. Data are combined from 2 independent experiments. Each experiment had 10 mice per group. Statistical significance assessed by the Gehan--Breslow--Wilcoxon test revealed no significant difference in colonization by WT versus Ω*siaT* in mice from Jackson. The underlying numerical data for this figure can be found in [S1 Data](#pbio.3000788.s013){ref-type="supplementary-material"}. CFU, colony-forming unit; *siaT*, predicted sialic acid transporter; WT, wild type.

(TIFF)

###### 

Click here for additional data file.

###### Vaginal sialidase activity in *E*. *coli*- and *F*. *nucleatum*-inoculated mice.

(A--B) Sialidase activity in vaginal washes from individual animals purchased from Envigo, estrogenized, and inoculated with *E*. *coli* (A) or *F*. *nucleatum* (B) from 1 to 8 dpi. The underlying numerical data for this figure can be found in [S1 Data](#pbio.3000788.s013){ref-type="supplementary-material"}. dpi, days postinoculation.

(TIFF)

###### 

Click here for additional data file.

###### Analysis of sialidase activity in vaginal swab eluates for selection of human vaginal communities.

\(A\) Graph shows relative sialidase activity in vaginal swabs that were transported aerobically from clinic to the lab. Sialidase activity was measured in swab eluates (*N* = 58) using a 4MU-Sia assay. Samples with a relative sialidase activity \>1.0 were considered to be sialidase-positive. Red = sialidase-positive specimens, green = blank swab controls, blue = buffer control. The underlying numerical data for this figure can be found in [S1 Data](#pbio.3000788.s013){ref-type="supplementary-material"}. 4MU, 4-methylumbelliferone.

(TIFF)

###### 

Click here for additional data file.

###### Sialidase activity amplification in *G*. *vaginalis* cocultured with *F*. *nucleatum*.

\(A\) Heat map shows relative sialidase activity in *G*. *vaginalis* (inoculum OD~600~ 0.0--0.05) cultured overnight with *F*. *nucleatum* Ω*siaT* (inoculum OD~600~ 0.0--0.1) in supplemented Columbia media. Data shown are representative of 2 independent experiments. OD, optical density; *siaT*, predicted sialic acid transporter.

(TIFF)

###### 

Click here for additional data file.

###### Mouse vaginal microbial communities---collection and amplification.

Step 1: collection of mouse vaginal washes. Publication of this animal image was approved by IACUC. Washes were pooled from mice cohoused in the same cage. A portion of vaginal wash pools was cultured in Columbia broth (referred to as "microbiota pools") to amplify the vaginal bacteria and frozen for subsequent use. Remaining pooled material was stored at −20°C. Step 2: on the day of the experiment, frozen microbiota pools were used to recover mouse vaginal bacteria by streaking out on supplemented Columbia blood plates in anaerobic chamber and incubating for 24 h at 37°C. Colonies from these plates were resuspended in liquid media either (a) for DNA extraction or (b) for coculture experiments with *F*. *nucleatum*. IACUC, Institutional Animal Care and Use Committee.

(TIFF)

###### 

Click here for additional data file.

###### Human vaginal microbial communities---collection and amplification.

Step 1: anaerobic and aerobic vaginal swabs were collected on the same day from each participant. Aerobic swabs were eluted in sodium acetate buffer (pH 5.5), and sialidase activity was checked in the swab eluates using fluorogenic 4MU-Neu5Ac substrate. Anaerobic swabs were eluted in 2× NYCIII media (in an anaerobic chamber) and the communities were "fresh frozen," without any amplification/overnight culture, by mixing with cryoprotectant and storing at −80°C. Step 2: on the day of the experiment, fresh-frozen anaerobic vaginal communities, from women who had detectable sialidase activity in their aerobic swab eluates, were thawed at 4°C and diluted 4-fold in NYCIII media (in an anaerobic chamber). The diluted communities were used for coculture experiments with *F*. *nucleatum*. Neu5Ac, *N*-acetylneuraminic acid; 4MU, 4-methylumbelliferone.

(TIFF)

###### 

Click here for additional data file.

###### Key bacterial strains, plasmids, and primers.

(PDF)

###### 

Click here for additional data file.

###### Genetic organization of the putative sialic acid catabolic gene cluster in *F*. *nucleatum* strain ATCC 23726.

ATCC, American Type Culture Collection.

(PDF)

###### 

Click here for additional data file.

###### Contains underlying numerical data for the graphs in Figs [1](#pbio.3000788.g001){ref-type="fig"}--[8](#pbio.3000788.g008){ref-type="fig"} and [S3](#pbio.3000788.s003){ref-type="supplementary-material"}--[S7](#pbio.3000788.s007){ref-type="supplementary-material"} Figs.

(XLSX)

###### 

Click here for additional data file.

###### Contains underlying data for [S3D Fig](#pbio.3000788.s003){ref-type="supplementary-material"}.

(XLSX)

###### 

Click here for additional data file.
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ATCC

:   American Type Culture Collection

BV

:   bacterial vaginosis; *catP*, chloramphenicol acetyltransferase; DMB, 1,2-diamino-4,5-methylenedioxybenzene

dpi

:   days postinoculation

hpi

:   hours postinoculation

HPLC

:   high-performance liquid chromatography

IP

:   intraperitoneal

LB

:   lysogeny broth

LOD

:   limit of detection

MWCO

:   molecular weight cutoff

NanA

:   *N*-acetylneuraminate lyase

Neu5Ac

:   *N*-acetylneuraminic acid

NR

:   nonredundant

OD

:   optical density

PBS

:   phosphate-buffered saline

RT-qPCR

:   reverse transcription--quantitative PCR

*siaT*

:   predicted sialic acid transporter

Sm^R^

:   streptomycin-resistant

*tuf*

:   Translation elongation factor Tu

UC

:   Urogenital Community

WT

:   wild type

3SL

:   3′-sialyllactose

4MU

:   4-methylumbelliferone
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29 Jan 2020

Dear Dr Lewis,

Thank you for submitting your manuscript entitled \"Glycan cross-feeding supports mutualism between Fusobacterium and the vaginal microbiota\" for consideration as a Research Article by PLOS Biology.

Your manuscript has now been evaluated by the PLOS Biology editorial staff as well as by an academic editor with relevant expertise and I am writing to let you know that we would like to send your submission out for external peer review.

However, before we can send your manuscript to reviewers, we need you to complete your submission by providing the metadata that is required for full assessment. To this end, please login to Editorial Manager where you will find the paper in the \'Submissions Needing Revisions\' folder on your homepage. Please click \'Revise Submission\' from the Action Links and complete all additional questions in the submission questionnaire.

Please re-submit your manuscript within two working days, i.e. by Jan 31 2020 11:59PM.

Login to Editorial Manager here: <https://www.editorialmanager.com/pbiology>

During resubmission, you will be invited to opt-in to posting your pre-review manuscript as a bioRxiv preprint. Visit <http://journals.plos.org/plosbiology/s/preprints> for full details. If you consent to posting your current manuscript as a preprint, please upload a single Preprint PDF when you re-submit.

Once your full submission is complete, your paper will undergo a series of checks in preparation for peer review. Once your manuscript has passed all checks it will be sent out for review.

Feel free to email us at <plosbiology@plos.org> if you have any queries relating to your submission.

Kind regards,

Lauren A Richardson, Ph.D

Senior Editor

PLOS Biology
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9 Apr 2020

Dear Dr Lewis,

Thank you very much for submitting your manuscript entitled \"Glycan cross-feeding supports mutualism between Fusobacterium and the vaginal microbiota\" for consideration as a Research Article at PLOS Biology. Thank you also for your patience as we completed our editorial process, and please accept my sincere apologies for the long delay in providing you with our decision. Your manuscript has been evaluated by the PLOS Biology editors, an Academic Editor with relevant expertise, and by three independent reviewers.

As you will see, the reviewers find your conclusions novel and interesting, but also raise several issues that need to be clarified. Reviewer 2 would like know if you have measured the level of free Neu5Ac in the vagina washes to see if it correlates with the increase of the presence of F. nucleatum. After consulting with the academic editor, we do feel that these measurements should be added to the manuscript, while the other points can be addresed by textual changes.

In light of the reviews (attached below), we are pleased to offer you the opportunity to address the comments from the reviewers in a revised version that we anticipate should not take you very long. We will then assess your revised manuscript and your response to the reviewers\' comments and we may consult the reviewers again.

We expect to receive your revised manuscript within 2 month, but please email us (<plosbiology@plos.org>) if you have any questions or concerns, or would like to request an extension - we completely understand that due to COVID-19 your lab might be close and it will take a while for you to be able to add the data requested. At this stage, your manuscript remains formally under active consideration at our journal; please notify us by email if you do not intend to submit a revision so that we may end consideration of the manuscript at PLOS Biology.

\*\*IMPORTANT - SUBMITTING YOUR REVISION\*\*

Your revisions should address the specific points made by each reviewer. Please submit the following files along with your revised manuscript:

1\. A \'Response to Reviewers\' file - this should detail your responses to the editorial requests, present a point-by-point response to all of the reviewers\' comments, and indicate the changes made to the manuscript.

\*NOTE: In your point by point response to the reviewers, please provide the full context of each review. Do not selectively quote paragraphs or sentences to reply to. The entire set of reviewer comments should be present in full and each specific point should be responded to individually.

You should also cite any additional relevant literature that has been published since the original submission and mention any additional citations in your response.

2\. In addition to a clean copy of the manuscript, please also upload a \'track-changes\' version of your manuscript that specifies the edits made. This should be uploaded as a \"Related\" file type.

\*Resubmission Checklist\*

When you are ready to resubmit your revised manuscript, please refer to this resubmission checklist: <https://plos.io/Biology_Checklist>

To submit a revised version of your manuscript, please go to <https://www.editorialmanager.com/pbiology/> and log in as an Author. Click the link labelled \'Submissions Needing Revision\' where you will find your submission record.

Please make sure to read the following important policies and guidelines while preparing your revision:

\*Published Peer Review\*

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out. Please see here for more details:

<https://blogs.plos.org/plos/2019/05/plos-journals-now-open-for-published-peer-review/>

\*PLOS Data Policy\*

Please note that as a condition of publication PLOS\' data policy (<http://journals.plos.org/plosbiology/s/data-availability>) requires that you make available all data used to draw the conclusions arrived at in your manuscript. If you have not already done so, you must include any data used in your manuscript either in appropriate repositories, within the body of the manuscript, or as supporting information (N.B. this includes any numerical values that were used to generate graphs, histograms etc.). For an example see here: <http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001908#s5>

\*Blot and Gel Data Policy\*

We require the original, uncropped and minimally adjusted images supporting all blot and gel results reported in an article\'s figures or Supporting Information files. We will require these files before a manuscript can be accepted so please prepare them now, if you have not already uploaded them. Please carefully read our guidelines for how to prepare and upload this data: <https://journals.plos.org/plosbiology/s/figures#loc-blot-and-gel-reporting-requirements>

\*Protocols deposition\*

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <https://journals.plos.org/plosbiology/s/submission-guidelines#loc-materials-and-methods>

Thank you again for your submission to our journal. We hope that our editorial process has been constructive thus far, and we welcome your feedback at any time. Please don\'t hesitate to contact us if you have any questions or comments.

Sincerely,

Ines

\--

Ines Alvarez-Garcia, PhD

Senior Editor

PLOS Biology

Carlyle House, Carlyle Road

Cambridge, CB4 3DN

+44 1223--446970
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Reviewers' comments

Rev. 1:

In their manuscript "Glycan cross-feeding supports mutualism between Fusobacterium and the vaginal microbiota", Agarwal et al set out to validate the hypothesis that the increased risk for pathogenic colonization observed in bacterial vaginosis patients is due (at least in part) to the increased presence of sialidases. Specifically, the authors look at the pathogen Fusobacterium nucleatum, which had been predicted to be able to catabolize free sialic-acid but does not possess sialidases. They generate a knockout (siaT) that is lacking key metabolic genes that block the ability of F. nucleatum to catabolize and grow in the presence of free sialic acid, which is then used as a control for the next experiments to distinguish between effects caused by the presence versus catabolic activity of F. nucleatum. Overall Agarwal et al present compelling evidence that certain strains of F.nucleatum can grow on free sialic acid and are thereby provided an advantage in environments where sialidases are present. However, there are some points in the manuscript that need clarification as detailed below.

Major Comments

\- The murine in vivo results show that only the WT, not siaT mutant, increase sialidase activity over time (Fig 5B+C). First, it is not clear if the siaT mutant increases sialidase activity compared to no infection control (albeit less than WT). Second, the murine ex vivo results show that both WT and siaT mutants increase sialidase activity in the vaginal microbial community. What accounts for this discrepancy between the in vivo and ex vivo data? This raises major concerns how translational these findings are.

\- In the human vaginal swab ex vivo data, only the WT F. nucleatum strain is used, I assume that is because there was a limited amount of sample but it would be interesting to see if the mutant results here reflect the in vivo or ex vivo results from the murine experiments. Additional experiments would help to address this question.

Minor Comments

\- Figure 6;

o Fig6; as written the experiment is not clear; frozen vaginal microbial communities were grown overnight and then mixed with an F. nucleatum strain to test for effect -- for how long were they grown again? It took me awhile to find this in Fig S1 (16hrs), I would recommend mentioning this in the results for improved clarity.

o Fig 6C shows the final F. nucleatum CFU count after incubation with the vaginal pools, but how much F. nucleatum was put in to start? Is this concentration-dependent? It would be nice to see that the amount added was similar between both strains at the beginning as well.

o The CFU input should be listed in Fig 6D (at a minimum in the legend if not on the figure) since right now it just shows qualitative increased input with triangles -- is the increasing input different by 2-fold? 10-fold? 0.1-fold??

\- Fig S4; Even though there is no difference between WT and KO colonization in Jackson mice, when comparing numbers to Envigo mice in Fig 4 it appears that the KO is better at colonizing in Jackson mice rather than the WT being worse (as I would expect since Jackson mice have low sialidase activity) -- maybe colonization in these mice is driven by different factors? I think it would be worthwhile to comment on this at least in the supplementary info.

\- Lines 260-270; the way this is currently written it sounds like sialidase activity was somehow determined from the extracted DNA -- clarifying that 16S rRNA gene amplicon sequencing was performed and in parallel that isolated colonies were screened for sialidase activity will improve the readability of this section.

\- Line 273; 'somewhat different' is not very descriptive, from Sup Fig3D it appears as though the communities are quite distinct, a PERMANOVA analysis would help strengthen this statement in the text .

\- Line289; clarify to lower CFU titers.

\- Fig5B; difficult to tell which groups the stars are signifying significance for, use bars like in 5C.

\- Fig S5; E.coli misspelled in legend (E.colii).

Rev. 2:

The manuscript reports the characterisation of sialic acid consumption by Fusobacterium nucleatum strains and the impact on sialic acid cross-feeding on F. nucleatum colonisation of the vaginal niche. Specific outputs include the characterisation of NanA (sialic acid lyase) and NanT (sialic acid transporter) as critical components of F. nucleatum sialic acid metabolism in vitro, the ability of F. nucleatum to benefit from a sialidase-rich vaginal microbiota and the impact of F. nucleatum on G. vaginalis. The methodology is sound, and the manuscript presents some very interesting and novel insights into the interplay between sialic acid catabolism and the vaginal microbiota.

Below some comments and suggestions to clarify some aspects of the manuscript.

In the first set of experiments, the authors compared the Neu5Ac levels of F. nucleatum strains grown on (rich?) growth medium as compared to un-inoculated medium but don\'t provide information (in Results or in Fig legend) on the composition of the medium and whether it was supplemented with Neu5Ac (using the semi-defined medium introduced on p. 8. This information should be provided. The analysis uses un-inoculated medium as a control, a more informative control would be to use medium with no Neu5Ac as carbohydrate source. The authors should also include in the Results section how the Neu5Ac concentrations were determined (p. 5), and how they measured free versus bound sialic acid (p.11).

The authors demonstrated that in vitro F. nucleatum is not able to utilise a synthetic sialylated substrate and that adding exogenous sialidase from Arthobacter ureafaciens enabled growth of F. nucleatum on this substrate. The interpretation of the data is based on growth measurements and supporting data such as measuring the Neu5Ac in the medium and/or the sialidase activity during growth would be needed to strengthen the interpretation. Also, the authors may comment why G. vaginalis and not Arthobacter ureafaciens was used as a control in the first growth experiment (L.213) or conversely why the sialidase from G. vaginalis was not used in the following experiment (from L.218). The authors should also provide information on the linkage of the substrate as differences in sialidase specificity of the bacteria tested will need to be considered when interpreting the results. Did the authors try and co-culture a sialidase-producing bacteria from the vaginal niche (e.g. G. vaginalis, Arthobacter ureafaciens or Enterococcus casseliflavus/gallinarum) with F. nucleatum on sialylated substrate?

With regards to the mouse work, the authors demonstrate a link between vaginal microbial sialidase activity and F. nucleatum colonisation. It is suprising that the authors did not measure the level of free Neu5Ac in the vaginal washes of the mice under study so to link the increase in F. nucleatum with increased availability of free Neu5Ac in mice displaying high sialidase activity. Did/could the authors carry out these investigations? These data would need to be included to be consistent with the title of the manuscript that glycan cross-feeding supports mutualism between Fusobacterium and the vaginal microbiota.

The last part of the study revealing an increase in microbial sialidase activity of mouse or human vaginal communities in the presence of F. nucleatum is interesting but, is more of an observation, and more work would be needed to strengthen this part of the work, which may be outsisde the scope of this manuscript. I would therefore suggest removing these last two sections from the manuscript as without further supporting data, the possible explanations provided are too speculative at this stage.

Minor comments.

The sentences L. 127 and L211 about the bioinformatics analysis of F. nucleatum \'proteomes\' are ambiguous, as this analysis is based on genome screening not on proteomics data.

Fig. 1 Legend requires clarification with regards to the growth medium used in the experiment and as control.

L.186,187. \'plateauing\' sounds like of Lab jargon and may be replaced by \'reaching a plateau\'

L. 274 the term used \'somewhat different\' vaginal microbiota is too vague and should be refined.

Rev. 3: Carl Yeoman -- please note that this reviewer has waived anonymity

Apologies for the delay, I really enjoyed reading this paper and felt it was another great and useful addition to the literature from the Gilbert lab. The manuscript describes a number of well designed and deployed experiments that examine the microbial ecology related to Fusobacterium nucleatum colonization and persistence of the vaginal microenvironment and a potential mutualism with G. vaginalis adding important insight into the ecological interactions underlying vaginal dysbiosis and related-diseases, with particular relevance to pre-term birth. I commend the authors on the amount of work that has clearly gone into this manuscript and the well thought out set of experiments. Below are only minor thoughts and comments for consideration:

Minor Comments:

Line 54: Beware of the creep in reporting of these statistical data - available data supports a little less than 30 % of US women are affected by BV, which has since been reported as 30 % and subsequently as a third of US women. This may seem small but is actually very large.

Lines 62 - 64: Aside from the grammatical error of placing the comma (which should probably be a semicolon) inside the brackets, this sentence appears to be miswritten - the healthy microbiome excluding potentially pathogenic members leads to dysbiosis?

Lines 481+ In addition to oro-vaginal contact, other routes have previously been proposed, including in the context of pre-term delivery (e.g. see Cobb et al. 2017. DOI: 10.2147/IJWH.S142730) and while I don\'t think evidence supports a placental microbiome, of relevance to this paper is the similarities 16S studies have found between the placenta and oral microbiota (e.g. Aagaard et al. 2016. DOI: 10.1126/scitranslmed.3008599).

10.1371/journal.pbio.3000788.r003
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29 May 2020

Dear Dr Lewis,

Thank you for submitting your revised Research Article entitled \"Glycan cross-feeding supports mutualism between Fusobacterium and the vaginal microbiota\" for publication in PLOS Biology. I have now discussed your revision with the team of editors and obtained advice from the Academic Editor.

We\'re delighted to let you know that we\'re now editorially satisfied with your manuscript. However before we can formally accept your paper and consider it \"in press\", we also need to ensure that your article conforms to our guidelines. A member of our team will be in touch shortly with a set of requests. As we can\'t proceed until these requirements are met, your swift response will help prevent delays to publication. Please also make sure to address the data and other policy-related requests noted at the end of this email.

\*Copyediting\*

Upon acceptance of your article, your final files will be copyedited and typeset into the final PDF. While you will have an opportunity to review these files as proofs, PLOS will only permit corrections to spelling or significant scientific errors. Therefore, please take this final revision time to assess and make any remaining major changes to your manuscript.
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